Abstract
Although PPAR subtypes share common features in terms of tissue distribution and ligand specificity, each subtype maintains a degree of individuality which enables it to perform subtype-specific functions. It has been established that PPARα, which is mainly expressed in the liver, heart, muscle, and kidney, augments fatty acid catabolism and acts as the molecular target for the lipid-lowering fibrate drugs. PPARβ/δ, in contrast, is ubiquitously expressed and is involved in the regulation of a variety of processes including keratinocyte differentiation, wound healing, inflammation, as well as glucose and lipid utilization. Finally, PPARγ is highly expressed in adipocytes and macrophages and is essential for adipocyte differentiation, lipid storage, and regulation of inflammation. PPARγ also mediates the activity of the insulin-sensitizing drugs thiazolidinediones and regulates glucose metabolism.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Abbott BD (2009) Review of the expression of peroxisome proliferator-activated-receptors alpha (PPAR alpha), beta (PPAR beta), and gamma (PPAR gamma) in rodent and human development. Reprod Toxicol 27:246–257
Aberle J, Hopfer I, Beil FU, Seedorf U (2006) Association of the T+294C polymorphism in PPAR delta with low HDL cholesterol and coronary heart disease risk in women. Int J Med 13:108–111
Adrian TE, Hennig R, Friess H, Ding X (2008) The role of PPAR gamma receptors and leukotriene B(4) receptors in mediating the effects of LY293111 in pancreatic cancer. PPAR Res 2008:827096
Afzelius BA (1965) The occurrence and structure of microbodies: a comparative study. J Cell Biol 26:835–843
Agrawal R, Jain P, Dikshit SN (2012) Balaglitazone: a second generation peroxisome proliferator-activated receptor (PPAR) gamma(γ) agonist. Mini Rev Med Chem 12:87–97
Aleksunes L, Yeager R, Klaassen C (2009) Application of multivariate statistical procedures to identify transcription factors that correlate with MRP2, 3, and 4 mRNA in adult human livers. Xenobiotica 39:514–522
Ali FY, Egan K, Fitzgerald GA, Desvergne B, Wahli W, Bishop-Bailey D, Warner TD, Mitchell JA (2005) Role of prostacyclin versus peroxisome proliferator-activated receptor beta receptors in prostacyclin sensing by lung fibroblasts. Am J Respir Cell Mol Biol 34:242–246
Allen T, Zhang F, Moodie SA, Clemens LE, Smith A, Gregoire F, Bell A, Muscat GE, Gustafson TA (2006) Halofenate is a selective peroxisome proliferator-activated receptor gamma modulator with antidiabetic activity. Diabetes 55:2523–2533
Almeida M, Ambrogini E, Han L, Manolagas SC, Jilka RL (2009) Increased lipid oxidation causes oxidative stress, increased peroxisome proliferator-activated receptor-gamma expression, and diminished pro-osteogenic Wnt signaling in the skeleton. J Biol Chem 284:27438–27448
Alnouti Y, Klaassen C (2006) Tissue distribution and ontogeny of sulfotransferase enzymes in mice. Toxicol Sci 93:242–255
Alnouti Y, Klaassen C (2008) Regulation of sulfotransferase enzymes by prototypical microsomal enzyme inducers in mice. J Pharmacol Exp Ther 324:612–621. doi:10.1124/jpet.107.129650
Alonso-Galicia M, Frohlich B, Roman RJ (1998) Induction of P4504A activity improves pressure-natriuresis in Dahl S rats. Hypertension 31:232–236
Alsarra I, Brockmann W, Cunningham M, Badr M (2006) Hepatocellular proliferation in response to agonists of peroxisome proliferator-activated receptor alpha: a role for kupffer cells? J Carcinog 5:26
Alvares K, Carillo A, Yuan PM, Kawano H, Morimoto RI, Reddy JK (1990) Identification of cytosolic peroxisome proliferator binding protein as a member of the heat shock protein HSP70 family. Proc Natl Acad Sci USA 87:5293–5297
Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM (1999) Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39:361–398
Ameshima S, Golpon H, Cool CD, Chan D, Vandivier RW, Gardai SJ, Wick M, Nemenoff RA, Geraci MW, Voelkel NF (2003) Peroxisome proliferator-activated receptor gamma (PPARgamma) expression is decreased in pulmonary hypertension and affects endothelial cell growth. Circ Res 92:1162–1169
Amin RH, Mathews ST, Camp HS, Ding L, Leff T (2010) Selective activation of PPARgamma in skeletal muscle induces endogenous production of adiponectin and protects mice from diet-induced insulin resistance. Am J Physiol Endocrinol Metab 298:E28–E37
Anderson SP, Dunn CS, Cattley RC, Corton JC (2001) Hepatocellular proliferation in response to a peroxisome proliferator does not require TNFalpha signaling. Carcinogenesis 22:1843–1851
Angeli V, Hammad H, Staels B, Capron M, Lambrecht BN, Trottein F (2003) Peroxisome proliferator-activated receptor gamma inhibits the migration of dendritic cells: consequences for the immune response. J Immunol 170:5295–5301
Angione AR, Jiang C, Pan D, Wang YX, Kuang S (2011) PPARdelta regulates satellite cell proliferation and skeletal muscle regeneration. Skelet Muscle 1:33
Aoyama T, Ikejima K, Kon K, Okumura K, Arai K, Watanabe S (2009) Pioglitazone promotes survival and prevents hepatic regeneration failure after partial hepatectomy in obese and diabetic KK-A(y) mice. Hepatology 49:1636–1644
Arias T, Beaumont J, López B, Zalba G, Beloqui O, Barba J, Valencia F, Gómez-Doblas JJ, De Teresa E, Díez J (2011) Association of the peroxisome proliferator-activated receptor α gene L162V polymorphism with stage C heart failure. J Hypertens 29:876–883
Asada K, Sasaki S, Suda T, Chida K, Nakamura H (2004) Antiinflammatory roles of peroxisome proliferator-activated receptor gamma in human alveolar macrophages. Am J Respir Crit Care Med 169:195–200
Asakawa M, Takano H, Nagai T, Uozumi H, Hasegawa H, Kubota N, Saito T, Masuda Y, Kadowaki T, Komuro I (2002) Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. Circulation 105:1240–1246
Asano M, Nakajima T, Iwasawa K, Morita T, Nakamura F, Imuta H, Chisaki K, Yamada N, Omata M, Okuda Y (1999) Troglitazone and pioglitazone attenuate agonist-dependent Ca2+ mobilization and cell proliferation in vascular smooth muscle cells. Br J Pharmacol 128:673–683
Avis I, Martínez A, Tauler J, Zudaire E, Mayburd A, Abu-Ghazaleh R, Ondrey F, Mulshine JL (2005) Inhibitors of the arachidonic acid pathway and peroxisome proliferator-activated receptor ligands have super additive effects on lung cancer growth inhibition. Cancer Res 65:4181–4190
Azuma YT, Nishiyama K, Matsuo Y, Kuwamura M, Morioka A, Nakajima H, Takeuchi T (2010) PPARα contributes to colonic protection in mice with DSS-induced colitis. Int Immunopharmacol 10:1261–1267
Badr M (2004) Peroxisome proliferator-activated receptor alpha and cancer: friends or foes? Int J Cancer Prev 1:77–87
Baes M, Aubourg P (2009) Peroxisomes, myelination and axonal integrity in the CNS. Neuroscientist 15:367–379
Bakke I, Hammer TA, Sandvik AK, Waldum HL (2002) PPAR alpha stimulates the rat gastrin-producing cell. Mol Cell Endocrinol 195:89–97
Barak Y, Kim S (2007) Genetic manipulations of PPARs: effects on obesity and metabolic disease. PPAR Res 2007:12781
Barak Y, Nelson MC, Ong ES, Jones YZ, Ruiz-Lozano P, Chien KR, Koder A, Evans RM (1999) PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol Cell 4:585–595
Barak Y, Liao D, He W, Ong ES, Nelson MC, Olefsky JM, Boland R, Evans RM (2002) Effects of peroxisome proliferator-activated receptor delta on placentation, adiposity, and colorectal cancer. Proc Natl Acad Sci USA 99:303–308
Barak Y, Sadovsky Y, Shalom-Barak T (2008) PPAR signaling in placental development and function. PPAR Res 2008:142082
Barger PM, Kelly DP (2000) PPAR signaling in the control of cardiac energy metabolism. Trends Cardiovasc Med 10:238–245
Barish GD, Atkins AR, Downes M, Olson P, Chong LW, Nelson M, Zou Y, Hwang H, Kang H, Curtiss L, Evans RM, Lee CH (2008) PPARdelta regulates multiple proinflammatory pathways to suppress atherosclerosis. Proc Natl Acad Sci USA 105:4271–4276
Barnett D, Craig JG, Robinson DS, Rogers MP (1977) Effect of clofibrate on glucose tolerance in maturity onset diabetes. Br J Clin Pharmacol 4:455–458
Barroso E, Rodríguez-Calvo R, Serrano-Marco L, Astudillo AM, Balsinde J, Palomer X, Vázquez-Carrera M (2011) The PPARβ/δ activator GW501516 prevents the down-regulation of AMPK caused by a high-fat diet in liver and amplifies the PGC-1α-Lipin 1-PPARα pathway leading to increased fatty acid oxidation. Endocrinology 152:1848–1859
Barter PJ, Rye KA (2008) Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome? Arterioscler Thromb Vasc Biol 28:39–46
Bassaganya-Riera J, Reynolds K, Martino-Catt S, Cui Y, Hennighausen L, Gonzalez F, Rohrer J, Benninghoff AU, Hontecillas R (2004) Activation of PPAR gamma and delta by conjugated linoleic acid mediates protection from experimental inflammatory bowel disease. Gastroenterology 127:777–791
Basu-Modak S, Braissant O, Escher P, Desvergne B, Honegger P, Wahli W (1999) Peroxisome proliferator-activated receptor beta regulates acyl-CoA synthetase 2 in reaggregated rat brain cell cultures. J Biol Chem 274:35881–35888
Baylis C, Atzpodien EA, Freshour G, Engels K (2003) Peroxisome proliferator-activated receptor [gamma] agonist provides superior renal protection versus angiotensin-converting enzyme inhibition in a rat model of type 2 diabetes with obesity. J Pharmacol Exp Ther 307:854–860
Bazargani A, Khoramrooz SS, Kamali-Sarvestani E, Taghavi SA, Saberifiroozi M (2010) Association between peroxisome proliferator-activated receptor-γ gene polymorphism (Pro12Ala) and Helicobacter pylori infection in gastric carcinogenesis. Scand J Gastroenterol 45:1162–1167
Beamer BA, Yen CJ, Andersen RE, Muller D, Elahi D, Cheskin LJ, Andres R, Roth J, Shuldiner AR (1998) Association of the Pro12Ala variant in the peroxisome proliferator-activated receptor-gamma2 gene with obesity in two Caucasian populations. Diabetes 47:1806–1808
Behshad R, Cooper KD, Korman NJ (2008) A retrospective case series review of the peroxisome proliferator-activated receptor ligand rosiglitazone in the treatment of atopic dermatitis. Arch Dermatol 144:84–88
Belvisi MG, Hele DJ (2008) Peroxisome proliferator-activated receptors as novel targets in lung disease. Chest 134:152–157
Belvisi MG, Hele DJ, Birrell MA (2006) Peroxisome proliferator-activated receptor gamma agonists as therapy for chronic airway inflammation. Eur J Pharmacol 533:101–109
Benayoun L, Letuve S, Druilhe A, Boczkowski J, Dombret MC, Mechighel P, Megret J, Leseche G, Aubier M, Pretolani M (2001) Regulation of peroxisome proliferator-activated receptor gamma expression in human asthmatic airways: relationship with proliferation, apoptosis, and airway remodeling. Am J Respir Crit Care Med 164:1487–1494
Benigni A, Zoja C, Tomasoni S, Campana M, Corna D, Zanchi C, Gagliardini E, Garofano E, Rottoli D, Ito T, Remuzzi G (2006) Transcriptional regulation of nephrin gene by peroxisome proliferator-activated receptor-gamma agonist: molecular mechanism of the antiproteinuric effect of pioglitazone. J Am Soc Nephrol 17:1624–1632
Bentley P, Calder I, Elcombe C, Grasso P, Stringer D, Wiegand HJ (1993) Hepatic peroxisome proliferation in rodents and its significance for humans. Food Chem Toxicol 31:857–907
Berfield AK, Chait A, Oram JF, Zager RA, Johnson AC, Abrass CK (2006) IGF-1 induces rat glomerular mesangial cells to accumulate triglyceride. Am J Physiol Renal Physiol 290:F138–F147
Berger J, Moller DF (2002) The mechanisms of action of PPARs. Annu Rev Med 53:409–435
Berhanu P, Perez A, Yu S (2007) Effect of pioglitazone in combination with insulin therapy on glycaemic control, insulin dose requirement and lipid profile in patients with type 2 diabetes previously poorly controlled with combination therapy. Diabetes Obes Metab 9:512–520
Bernardo A, Minghetti L (2008) Regulation of glial cell functions by PPAR-gamma natural and synthetic agonists. PPAR Res 2008:864140
Berria R, Glass L, Mahankali A, Miyazaki Y, Monroy A, De Filippis E, Cusi K, Cersosimo E, Defronzo RA, Gastaldelli A (2007) Reduction in hematocrit and hemoglobin following pioglitazone treatment is not hemodilutional in Type II diabetes mellitus. Clin Pharmacol Ther 82:275–281
Besson VC, Chen XR, Plotkine M, Marchand-Verrecchia C (2005) Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, exerts neuroprotective effects in traumatic brain injury. Neurosci Lett 388:7–12
Bihan H, Rouault C, Reach G, Poitout V, Staels B, Guerre-Millo M (2005) Pancreatic islet response to hyperglycemia is dependent on peroxisome proliferator-activated receptor alpha (PPARalpha). FEBS Lett 579:2284–2288
Bility MT, Devlin-Durante MK, Blazanin N, Glick AB, Ward JM, Kang BH, Kennett MJ, Gonzalez FJ, Peters JM (2008) Ligand activation of peroxisome proliferator-activated receptor beta/delta (PPAR beta/delta) inhibits chemically induced skin tumorigenesis. Carcinogenesis 29:2406–2414
Billoni N, Buan B, Gautier B, Collin C, Gaillard O, Mahé YF, Bernard BA (2000) Expression of peroxisome proliferator activated receptors (PPARs) in human hair follicles and PPAR alpha involvement in hair growth. Acta Derm Venereol 80:329–334
Blasi ER, Heyen J, Hemkens M, McHarg A, Ecelbarger CM, Tiwari S (2009) Effects of chronic PPAR-agonist treatment on cardiac structure and function, blood pressure, and kidney in healthy Sprague–Dawley rats. PPAR Res 2009:237865
Blumcke S, Schwartzkopff W, Lobeck H, Edmondson NA, Prentice DE, Blane GF (1983) Influence of fenofibrate on cellular and subcellular liver structure in hyperlipidemic patients. Atherosclerosis 46:105–116
Bojes HK, Germolec DR, Simoeonova P, Bruccoleri A, Schoonhoven R, Luster MI, Thurman RG (1997) Antibodies to tumor necrosis factor α prevent increases in cell replication in liver due to the potent peroxisome proliferator, Wy-14,643. Carcinogenesis 18:669–674
Bonofiglio D, Cione E, Qi H, Pingitore A, Perri M, Catalano S, Vizza D, Panno ML, Genchi G, Fuqua SA, Andò S (2009) Combined low doses of PPARgamma and RXR ligands trigger an intrinsic apoptotic pathway in human breast cancer cells. Am J Pathol 75:1270–1280
Borbath I, Horsmans Y (2008) The role of PPARgamma in hepatocellular carcinoma. PPAR Res 2008:209520
Borbath I, Leclercq I, Moulin P, Sempoux C, Horsmans Y (2007) The PPARgamma agonist pioglitazone inhibits early neoplastic occurrence in the rat liver. Eur J Cancer 43:1755–1763
Bordet R, Ouk T, Petrault O, Gelé P, Gautier S, Laprais M, Deplanque D, Duriez P, Staels B, Fruchart JC, Bastide M (2006) PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases. Biochem Soc Trans 34:1341–1346
Botton T, Puissant A, Bahadoran P, Annicotte JS, Fajas L, Ortonne JP, Gozzerino G, Zamoum T, Tartare-Deckert S, Bertolotto C, Ballotti R, Rocchi S (2009) In vitro and in vivo anti-melanoma effects of ciglitazone. J Invest Dermatol 129:1208–1218
Bouaboula M, Hilairet S, Marchand J, Fajas L, Le Fur G, Casellas P (2005) Anandamide induced PPARgamma transcriptional activation and 3T3-L1 preadipocyte differentiation. Eur J Pharmacol 517:174–178
Braissant O, Wahli W (1998) Differential expression of peroxisome proliferator-activated receptor-alpha, -beta, and -gamma during rat embryonic development. Endocrinology 139:2748–2754
Braissant O, Foufelle F, Scotto C, Dauça M, Wahli W (1996) Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 137:354–366
Breidert T, Callebert J, Heneka MT, Landreth G, Launay JM, Hirsch EC (2002) Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson’s disease. J Neurochem 82:615–624
Bren-Mattison Y, Van Putten V, Chan D, Winn R, Geraci MW, Nemenoff RA (2005) Peroxisome proliferator-activated receptor-gamma (PPARgamma) inhibits tumorigenesis by reversing the undifferentiated phenotype of metastatic non-small-cell lung cancer cells (NSCLC). Oncogene 24:1412–1422
Bren-Mattison Y, Meyer AM, Van Putten V, Li H, Kuhn K, Stearman R, Weiser-Evans M, Winn RA, Heasley LE, Nemenoff RA (2008) Antitumorigenic effects of peroxisome proliferator-activated receptor-gamma in non-small-cell lung cancer cells are mediated by suppression of cyclooxygenase-2 via inhibition of nuclear factor-kappaB. Mol Pharmacol 37:709–717
Brockman JA, Gupta RA, Dubois RN (1998) Activation of PPARgamma leads to inhibition of anchorage-independent growth of human colorectal cancer cells. Gastroenterol 115:1049–1055
Brown MD, Shuldiner AR, Ferrell RE, Weiss EP, Korytkowski MT, Zmuda JM, McCole SD, Moore GE, Hagberg JM (2001) FABP2 genotype is associated with insulin sensitivity in older women. Metabolism 50:1102–1105
Brownstein J, Murphy S, Goldfine A, Grant RW, Sordo M, Gainer V, Colecchi JA, Dubey A, Nathan DM, Glaser JP, Kohane IS (2010) Rapid identification of myocardial infarction risk associated with diabetes medications using electronic medical records. Diabetes Care 33:526–531
Brun R, Tontonoz P, Forman B, Ellis R, Chen J, Evans R, Spiegelman B (1996) Differential activation of adipogenesis by multiple PPAR isoforms. Genes Dev 10:974–984
Bugge A, Mandrup S (2010) Molecular mechanisms and genome-wide aspects of PPAR subtype specific transactivation. PPAR Res 2010:169506
Burgess HA, Daugherty LE, Thatcher TH, Lakatos HF, Ray DM, Redonnet M, Phipps RP, Sime PJ (2005) PPARgamma agonists inhibit TGF-beta induced pulmonary myofibroblast differentiation and collagen production: implications for therapy of lung fibrosis. Am J Physiol Lung Cell Mol Physiol 288:L1146–L1153
Calkin AC, Thomas MC (2008) PPAR agonists and cardiovascular disease in diabetes. PPAR Res 2008:245–410
Cantello BC, Cawthorne MA, Cottam GP, Duff PT, Haigh D, Hindley RM, Lister CA, Smith SA, Thurlby PL (1994) [[omega-(Heterocyclyamino)alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents. J Med Chem 37:3977–3985
Cantini G, Lombardi A, Borgogni E, Francalanci M, Ceni E, Degl'Innocenti S, Gelmini S, Poli G, Galli A, Serio M, Forti G, Luconi M (2010) Peroxisome-proliferator-activated receptor gamma (PPARgamma) is required for modulating endothelial inflammatory response through a nongenomic mechanism. Eur J Cell Biol 89:645–653
Cao LQ, Chen XL, Wang Q, Huang XH, Zhen MC, Zhang LJ, Li W, Bi J (2007) Upregulation of PTEN involved in rosiglitazone-induced apoptosis in human hepatocellular carcinoma cells. Acta Pharmacol Sin 28:879–887
Capanni M, Calella F, Biagini MR, Genise S, Raimondi L, Bedogni G, Svegliati-Baroni G, Sofi F, Milani S, Abbate R, Surrenti C, Casini A (2006) Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study. Aliment Pharm Therap 23:1143–1151
Catalano M, Cortelazzo A, Santi R, Contino L, Demicheli M, Yilmaz Y, Zorzetto M, Campo I, Lanati N, Emanuele E (2008) The Pro12Ala polymorphism of peroxisome proliferator-activated receptor-gamma2 gene is associated with plasma levels of soluble RAGE (Receptor for Advanced Glycation Endproducts) and the presence of peripheral arterial disease. Clin Biochem 41:981–985
Cattley RC, DeLuca J, Elconbe C, Fenner-Crisp P, Lake BG, Marsman DS, Pastor TA, Popp JA, Robinson DE, Schwetz B, Tugwood J, Wahli W (1998) Do peroxisome proliferating compounds pose a hepatocarcinogenic hazard to humans? Regul Toxicol Pharmacol 27:47–60
Cazzola M, Matera MG, Rogliani P, Page C (2007) Treating systemic effects of COPD. Trends Pharmacol Sci 28:544–550
Cha DR, Zhang X, Zhang Y, Wu J, Su D, Han JY, Fang X, Yu B, Breyer MD, Guan Y (2007) Peroxisome proliferator activated receptor alpha/gamma dual agonist tesaglitazar attenuates diabetic nephropathy in db/db mice. Diabetes 56:2036–2045
Chakravarthy MV, Lodhi IJ, Yin L, Malapaka RR, Xu HE, Turk J, Semenkovich CF (2009) Identification of a physiologically relevant endogenous ligand for PPARalpha in liver. Cell 138:476–488
Chan BY, Gartland A, Wilson PJ, Buckley KA, Dillon JP, Fraser WD, Gallagher JA (2007) PPAR agonists modulate human osteoclast formation and activity in vitro. Bone 40:149–159
Chandra V, Huang P, Hamuro Y, Raghuram S, Wang Y, Burris TP, Rastinejad F (2008) Structure of the intact PPAR-gamma-RXR-alpha nuclear receptor complex on DNA. Nature 456:350–356
Chang TH, Szabo E (2000) Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor gamma in non-small cell lung cancer. Cancer Res 60:1129–1138
Chang AY, Wyse BM, Gilchrist BJ, Peterson T, Diani AR (1983) Ciglitazone, a new hypoglycemic agent. I. Studies in ob/ob and db/db mice, diabetic Chinese hamsters and normal and streptozotosin-diabetic rats. Diabetes 32:830–838
Chearwae W, Bright JJ (2008) PPARgamma agonists inhibit growth and expansion of CD133+ brain tumour stem cells. Br J Cancer 99:2044–2053
Cheatham WW (2010) Peroxisome proliferator-activated receptor translational research and clinical experience. Am J Clin Nutr 91:262S–266S
Chen YX, Zhong XY, Qin YF, Bing W, He LZ (2003) 15d-PGJ2 inhibits cell growth and induces apoptosis of MCG-803 human gastric cancer cell line. World J Gastroenterol 9:2149–2153
Chen L, Bush CR, Necela BM, Su W, Yanagisawa M, Anastasiadis PZ, Fields AP, Thompson EA (2006) RS5444, a novel PPARgamma agonist, regulates aspects of the differentiated phenotype in nontransformed intestinal epithelial cells. Mol Cell Endocrinol 251:17–32
Chen S, Li Y, Li S, Yu C (2008a) A Val227Ala substitution in the peroxisome proliferator activated receptor alpha (PPAR alpha) gene associated with non-alcoholic fatty liver disease and decreased waist circumference and waist-to-hip ratio. J Gastroenterol Hepatol 23:1415–1418
Chen D, Jin G, Wang Y, Wang H, Liu H, Liu Y, Fan W, Ma H, Miao R, Hu Z, Sun W, Qian J, Jin L, Wei Q, Shen H, Huang W, Lu D (2008b) Genetic variants in peroxisome proliferator-activated receptor-gamma gene are associated with risk of lung cancer in a Chinese population. Carcinogenesis 29:342–350
Chen H, He YW, Liu WQ, Zhang JH (2008c) Rosiglitazone prevents murine hepatic fibrosis induced by Schistosoma japonicum. World J Gastroenterol 14:2905–2911
Chen C, Xu S, Wang WX, Ding YM, Yu KH, Wang B, Chen XY (2009) Rosiglitazone attenuates the severity of sodium taurocholate-induced acute pancreatitis and pancreatitis-associated lung injury. Arch Med Res 40:79–88
Cheon CW, Kim DH, Kim DH, Cho YH, Kim JH (2009) Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol 15:310–320
Cheung C, Akiyama TE, Ward JM, Nicol CJ, Feigenbaum L, Vinson C, Gonzalez FJ (2004) Diminished hepatocellular proliferation in mice humanized for the nuclear receptor peroxisome proliferator-activated receptor alpha. Cancer Res 64:3849–3854
Chikahisa S, Tominaga K, Kawai T, Kitaoka K, Oishi K, Ishida N, Rokutan K, Séi H (2008) Bezafibrate, a peroxisome proliferator-activated receptors agonist, decreases body temperature and enhances electroencephalogram delta-oscillation during sleep in mice. Endocrinology 149:5262–5271
Chima RS, Hake PW, Piraino G, Mangeshkar P, Denenberg A, Zingarelli B (2008) Ciglitazone ameliorates lung inflammation by modulating the inhibitor kappaB protein kinase/nuclear factor-kappaB pathway after hemorrhagic shock. Crit Care Med 36:2849–2857
Chinetti G, Fruchart JC, Staels B (2000) Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res 49:497–505
Chopra B, Georgopoulos NT, Nicholl A, Hinley J, Oleksiewicz MB, Southgate J (2009) Structurally diverse peroxisome proliferator-activated receptor agonists induce apoptosis in human uro-epithelial cells by a receptor-independent mechanism involving store-operated calcium channels. Cell Prolif 42:688–700
Christopoulos P, Mastorakos G, Gazouli M, Deligeoroglou E, Katsikis I, Diamanti-Kandarakis E, Panidis D, Creatsas G (2010) Peroxisome proliferator-activated receptor-γ and -δ polymorphisms in women with polycystic ovary syndrome. Ann NY Acad Sci 1205:185–191
Chrousos GP (2007) The PPARdelta agonist GW501516 suppresses interleukin-6-mediated hepatocyte acute phase reaction via STAT3 inhibition. Eur J Clin Invest 37:425–433
Coleman JD, Prabhu KS, Thompson JT, Reddy PS, Peters JM, Peterson BR, Reddy CC, Vanden Heuvel JP (2007) The oxidative stress mediator 4-hydroxynonenal is an intracellular agonist of the nuclear receptor peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta). Free Radic Biol Med 42:1155–1164
Corton JC, Fan LQ, Brown S, Anderson SP, Bocos C, Cattley RC, Mode A, Gustafsson JA (1998) Down-regulation of cytochrome P450 2C family members and positive acute-phase response gene expression by peroxisome proliferator chemicals. Mol Pharmacol 54:463–473
Costet P, Legendre C, Moré J, Edgar A, Galtier P, Pineau T (1998) Peroxisome proliferator-activated receptor alpha-isoform deficiency leads to progressive dyslipidemia with sexually dimorphic obesity and steatosis. J Biol Chem 273:29577–29585
Cottet J, Redel J, Krumm-Heller C, Tricaud ME (1953) Hypocholesterolemic property of sodium phenyl ethyl acetate (22 TH) in the rat. Bull Acad Natl Med 137:441–442
Coulter-Mackie MB, White CT, Hurley RM, Chew BH, Lange D (2011) Primary hyperoxaluria type 1. In: Pagon RA, Bird TD, Dolan CR, Stephens K, Adam MP (eds) GeneReviews™ [Internet]. University of Washington, Seattle, WA, 1993–2002. Jun 19 [updated 2011 Nov 17]
Crabb DW, Galli A, Fischer M, You M (2004) Molecular mechanisms of alcoholic fatty liver: role of peroxisome proliferator-activated receptor alpha. Alcohol 34:35–38
Crossno JT Jr, Morris KG Jr, Klemm DJ (2005) Attenuation of hypoxia-induced pulmonary artery remodeling by a peroxisome proliferator-activated receptor-gamma agonist. Chest 128:580S
Cuzzocrea S, Pisano B, Dugo L, Ianaro A, Patel NS, Di Paola R, Genovese T, Chatterjee PK, Di Rosa M, Caputi AP, Thiemermann C (2003) Rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2, ligands of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), reduce ischaemia/reperfusion injury of the gut. Br J Pharmacol 140:366–376
Cuzzocrea S, Bruscoli S, Mazzon E, Crisafulli C, Donato V, Di Paola R, Velardi E, Esposito E, Nocentini G, Riccardi C (2008) Peroxisome proliferator-activated receptor-alpha contributes to the anti-inflammatory activity of glucocorticoids. Mol Pharmacol 73:323–337
Dahten A, Koch C, Ernst D, Schnöller C, Hartmann S, Worm M (2008) Systemic PPARgamma ligation inhibits allergic immune response in the skin. J Invest Dermatol 128:2211–2218
Danawati CW, Nagata M, Moriyama H, Hara K, Yasuda H, Nakayama M, Kotani R, Yamada K, Sakata M, Kurohara M, Wiyono P, Asdie H, Sakaue M, Taniguchi H, Yokono K (2005) A possible association of Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma2 gene with obesity in native Javanese in Indonesia. Diabetes Metab Res Rev 21:465–469
D’Angelo B, Benedetti E, Di Loreto S, Cristiano L, Laurenti G, Cerù MP, Cimini A (2011) Signal transduction pathways involved in PPARβ/δ-induced neuronal differentiation. J Cell Physiol 226:2170–2180
David V, Martin A, Lafage-Proust MH, Malaval L, Peyroche S, Jones DB, Vico L, Guignandon A (2007) Mechanical loading down-regulates peroxisome proliferator-activated receptor gamma in bone marrow stromal cells and favors osteoblastogenesis at the expense of adipogenesis. Endocrinology 148:2553–2562
Davidson MH, Armani A, McKenney JM, Jacobson TA (2007) Safety considerations with fibrate therapy. Am J Cardiol 99(6A):3C–18C
Davis BJ, Maronpot RR, Heindel JJ (1994) Di-(2-ethylhexyl) phthalate suppresses estradiol and ovulation in cycling rats. Toxicol Appl Pharm 128:216–223
de Lange P, Lombardi A, Silvestri E, Goglia F, Lanni A, Moreno M (2008) Peroxisome proliferator-activated receptor delta: a conserved director of lipid homeostasis through regulation of the oxidative capacity of muscle. PPAR Res 2008:172676
de Vogel-van den Bosch HM, Bünger M, de Groot PJ, Bosch-Vermeulen H, Hooiveld GJ, Müller M (2008) PPARalpha-mediated effects of dietary lipids on intestinal barrier gene expression. BMC Genomics 9:231
Degenhardt T, Väisänen S, Rakhshandehroo M, Kersten S, Carlberg C (2009) Peroxisome proliferator-activated receptor alpha controls hepatic heme biosynthesis through ALAS1. J Mol Biol 388:225–238
Delayre-Orthez C, Becker J, Auwerx J, Frossard N, Pons F (2008) Suppression of allergen-induced airway inflammation and immune response by the peroxisome proliferator-activated receptor-alpha agonist fenofibrate. Eur J Pharmacol 581:177–184
Delerive P, Furman C, Teissier E, Fruchart J, Duriez P, Staels B (2000) Oxidized phospholipids activate PPARalpha in a phospholipase A2-dependent manner. FEBS Lett 47:34–38
Delerive P, Fruchart JC, Staels B (2001) Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol 169:453–459
Demerjian M, Man MQ, Choi EH, Brown BE, Crumrine D, Chang S, Mauro T, Elias PM, Feingold KR (2006) Topical treatment with thiazolidinediones, activators of peroxisome proliferator-activated receptor-gamma, normalizes epidermal homeostasis in a murine hyperproliferative disease model. Exp Dermatol 15:154–160
Desreumaux P, Dubuquoy L, Nutten S, Peuchmaur M, Englaro W, Schoonjans K, Derijard B, Desvergne B, Wahli W, Chambon P, Leibowitz MD, Colombel JF, Auwerx J (2001) Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategies. J Exp Med 193:827–838
Di Paola R, Crisafulli C, Mazzon E, Esposito E, Paterniti I, Galuppo M, Genovese T, Thiemermann C, Cuzzocrea S (2010) GW0742, a high-affinity PPAR -beta/delta agonist, inhibits acute lung injury in mice. Shock 33:426–435
Diep QN, El Mabrouk M, Cohn JS, Endemann D, Amiri F, Virdis A, Neves MF, Schiffrin EL (2002) Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-gamma. Circulation 105:2296–2302
Di-Poï N, Ng CY, Tan NS, Yang Z, Hemmings BA, Desvergne B, Michalik L, Wahli W (2005) Epithelium-mesenchyme interactions control the activity of peroxisome proliferator-activated receptor beta/delta during hair follicle development. Mol Cell Biol 25:1696–1712
Doney A, Fischer B, Frew D, Cumming A, Flavell DM, World M, Montgomery HE, Boyle D, Morris A, Palmer CN (2002) Haplotype analysis of the PPARgamma Pro12Ala and C1431T variants reveals opposing associations with body weight. BMC Genet 3:21
Doney AS, Fischer B, Cecil JE, Boylan K, McGuigan FE, Ralston SH, Morris AD, Palmer CN (2004) Association of the Pro12Ala and C1431T variants of PPARG and their haplotypes with susceptibility to Type 2 diabetes. Diabetologia 47:555–558
Dong YW, Wang XP, Wu K (2009) Suppression of pancreatic carcinoma growth by activating peroxisome proliferator-activated receptor gamma involves angiogenesis inhibition. World J Gastroenterol 15:441–448
Donohue TM Jr (2007) Alcohol-induced steatosis in liver cells. World J Gastroenterol 13:4974–4978
Dormandy J, Charbonnel B, Eckland D, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefèbvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Korányi L, Laakso M, Mokán M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized controlled trial. Lancet 366:1279–1289
Dowell P, Ishmael JE, Avram D, Peterson VJ, Nevrivy DJ, Leid M (1997) p300 functions as a coactivator for the peroxisome proliferator-activated receptor alpha. J Biol Chem 272:33435–33443
Downie MM, Sanders DA, Maier LM, Stock DM, Kealey T (2004) Peroxisome proliferator-activated receptor and farnesoid X receptor ligands differentially regulate sebaceous differentiation in human sebaceous gland organ cultures in vitro. Br J Dermatol 151:766–775
Dreyer C, Krey G, Keller H, Givel F, Helftenbeing G, Wahli W (1992) Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. Cell 68:879–887
Dreyer C, Keller H, Mahfoudi A, Laudet V, Krey G, Wahli W (1993) Positive regulation of peroxisomal beta-oxidation pathway by fatty acids through activation of peroxisome proliferator–activated receptors (PPAR). Biol Cell 77:67–76
Dubois M, Pattou F, Kerr-Conte J, Gmyr V, Vandewalle B, Desreumaux P, Auwerx J, Schoonjans K, Lefebvre J (2000) Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in normal human pancreatic islet cells. Diabetologia 43:1165–1169
Dubrac S, Schmuth M (2006) (P)PARsing epidermal development. J Invest Dermatol 126:241–242
Dubrac S, Schmuth M (2011) PPAR-alpha in cutaneous inflammation. Dermato-endocrinol 3:23–26
Dubuquoy L, Jansson EA, Deeb S, Rakotobe S, Karoui M, Colombel JF, Auwerx J, Pettersson S, Desreumaux P (2003) Impaired expression of peroxisome proliferator-activated receptor gamma in ulcerative colitis. Gastroenterology 124:1265–1276
Dubuquoy L, Rousseaux C, Thuru X, Peyrin-Biroulet L, Romano O, Chavatte P, Chamaillard M, Desreumaux P (2006) PPARgamma as a new therapeutic target in inflammatory bowel diseases. Gut 55:1341–1349
Duez H, Chao YS, Hernandez M, Torpier G, Poulain P, Mundt S, Mallat Z, Teissier E, Burton CA, Tedgui A, Fruchart JC, Fiévet C, Wright SD, Staels B (2002) Reduction of atherosclerosis by the peroxisome proliferator-activated receptor alpha agonist fenofibrate in mice. J Biol Chem 277:48051–48057
Dutheil F, Dauchy S, Diry M, Sazdovitch V, Cloarec O, Mellottée L, Bièche I, Ingelman-Sundberg M, Flinois JP, de Waziers I, Beaune P, Declèves X, Duyckaerts C, Loriot M (2009) Xenobiotic-metabolizing enzymes and transporters in the normal human brain: regional and cellular mapping as a basis for putative roles in cerebral function. Drug Metab Dispos 37:1528–1538
Dutton G (1980) Glucuronidation of drugs and other compounds. CRC Press, Boca Raton
Duval C, Chinetti G, Trottein F, Fruchart JC, Staels B (2002) The role of PPARs in atherosclerosis. Trends Mol Med 8:422–430
Efrati S, Berman S, Chachashvili A, Cohen N, Siman-Tov Y, Averbukh Z, Weissgarten J (2009) Rosiglitazone treatment attenuates renal tissue inflammation generated by urinary tract obstruction. Nephrology (Carlton) 14:189–197
Ehrenborg E, Krook A (2009) Regulation of skeletal muscle physiology and metabolism by peroxisome proliferator-activated receptor delta. Pharmacol Rev 61:373–393
Eibl G (2008) The role of PPAR-gamma and its interaction with COX-2 in pancreatic cancer. PPAR Res 2008:326915
Ellis CN, Varani J, Fisher GJ, Zeigler ME, Pershadsingh HA, Benson SC, Chi Y, Kurtz TW (2000) Troglitazone improves psoriasis and normalizes models of proliferative skin disease: ligands for peroxisome proliferator-activated receptor-gamma inhibit keratinocyte proliferation. Arch Dermatol 136:609–616
Enger C, Gately R, Ming EE, Niemcryk SJ, Williams L, McAfee AT (2010) Pharmacoepidemiology safety study of fibrate and statin concomitant therapy. Am J Cardiol 106:1594–1601
Erdmann E, Spanheimer R, Charbonnel B (2010) Pioglitazone and the risk of cardiovascular events in patients with type 2 diabetes receiving concomitant treatment with nitrates, renin-angiotensin system blockers, or insulin: results from the PROactive study (PROactive 20). J Diabetes 2:212–220
Esposito E, Cuzzocrea S (2011) Targeting the peroxisome proliferator-activated receptors (PPARs) in spinal cord injury. Expert Opin Ther Targets 15:943–959
Evans RM (1988) The steroid and thyroid hormone receptor superfamily. Science 240:889–895
Evans RM (2004) A transcriptional basis for physiology. Nat Med 10:1022–1026
Evans D, de Heer J, Hagemann C, Wendt D, Wolf A, Beisiegel U, Mann WA (2001) Association between the P12A and c1431t polymorphisms in the peroxisome proliferator activated receptor gamma (PPAR gamma) gene and type 2 diabetes. Exp Endocrinol Diabetes 109:151–154
Fahrbach SE, Smagghe G, Velarde RA (2011) Insect nuclear receptors. Annu Rev Entomol 57:83–106
Fajas L, Auboeuf D, Raspé E, Schoonjans K, Lefebvre AM, Saladin R, Najib J, Laville M, Fruchart JC, Deeb S, Vidal-Puig A, Flier J, Briggs MR, Staels B, Vidal H, Auwerx J (1997) The organization, promoter analysis, and expression of the human PPARgamma gene. J Biol Chem 272:18779–18789
Fajas L, Fruchart JC, Auwerx J (1998) PPARgamma3 mRNA: a distinct PPARgamma mRNA subtype transcribed from an independent promoter. FEBS Lett 438:55–60
Fang H, Strom S, Cai H, Falany C, Kocarek T, Runge-Morris M (2005) Regulation of human hepatic hydroxysteroid sulfotransferase gene expression by the peroxisome proliferator-activated receptor α transcription factor. Mol Pharmacol 67:1257–1267. doi:10.1124/mol.104.005389
Feige JN, Gelman L, Tudor C, Engelborghs Y, Wahli W, Desvergne B (2005) Fluorescence imaging reveals the nuclear behavior of peroxisome proliferator-activated receptor/retinoid X receptor heterodimers in the absence and presence of ligand. J Biol Chem 280:17880–17890
Feige NJ, Gelman L, Michalik L, Desvergne B, Wahli W (2006) From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. Prog Lipid Res 45:120–159
Feng D, Zhang Y, Chen G (2008) Cortical expression of peroxisome proliferator-activated receptor-alpha after human brain contusion. J Int Med Res 36:783–791
Ferdinandusse S, Denis S, Clayton PT, Graham A, Rees JE, Allen JT, McLean BN, Brown AY, Vreken P, Waterham HR, Wanders RJ (2000) Mutations in the gene encoding peroxisomal alpha-methylacyl-CoA racemase cause adult-onset sensory motor neuropathy. Nat Genet 24:188–191
Fernandes-Santos C, Evangelista Carneiro R, de Souza ML, Barbosa Aguila M, Mandarim-de-Lacerda CA (2009) Rosiglitazone aggravates nonalcoholic fatty pancreatic disease in C57BL/6 mice fed high-fat and high-sucrose diet. Pancreas 38:e80–e86
Fidaleo M (2010) Peroxisomes and peroxisomal disorders: the main facts. Exp Toxicol Pathol 62:615–625
Fievet C, Fruchart JC, Stales B (2006) PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and metabolic syndrome. Curr Opin Pharmacol 6:606–614
Fischer M, You M, Matsumoto M, Crabb DW (2003) Peroxisome proliferator-activated receptor alpha (PPARalpha) agonist treatment reverses PPARalpha dysfunction and abnormalities in hepatic lipid metabolism in ethanol-fed mice. J Biol Chem 278:27997–28004
Flavell DM, Pineda Torra I, Jamshidi Y, Evans D, Diamond JR, Elkeles RS, Bujac SR, Miller G, Talmud PJ, Staels B, Humphries SE (2000) Variation in the PPARalpha gene is associated with altered function in vitro and plasma lipid concentrations in type II diabetic subjects. Diabetologia 43:673–680
Flavell DM, Jamshidi Y, Hawe E, Pineda Torra I, Taskinen MR, Frick MH, Nieminen MS, Kesäniemi YA, Pasternack A, Staels B, Miller G, Humphries SE, Talmud PJ, Syvänne M (2002) Peroxisome proliferator-activated receptor alpha gene variants influence progression of coronary atherosclerosis and risk of coronary artery disease. Circulation 105:1440–1445
Fong D, Contreras R (2009) Glitazone use associated with diabetic macular edema. Am J Ophthalmol 147:583–586
Foreman JE, Chang SC, Ehresman DJ, Butenhoff JL, Anderson CR, Palkar PS, Kang BH, Gonzalez FJ, Peters JM (2009) Differential hepatic effects of perfluorobutyrate mediated by mouse and human PPAR-alpha. Toxicol Sci 110:204–211
Forman BM, Chen J, Evans RM (1997) Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci USA 94:4312–4317
Foxworthy PS, White SL, Hoover DM, Eacho PL (1990) Effect of ciprofibrate, bezafibrate and LY171883 on peroxisomal beta-oxidation in cultured rat, dog and rhesus monkey hepatocytes. Toxicol Appl Pharmacol 104:386–394
Fried LF, Orchard TJ, Kasiske BL (2001) Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 59:260–269
Fritz T, Krämer DK, Karlsson HK, Galuska D, Engfeldt P, Zierath JR, Krook A (2006) Low-intensity exercise increases skeletal muscle protein expression of PPARdelta and UCP3 in type 2 diabetic patients. Diabetes Metab Res Rev 22:492–498
Froment P (2008) PPARs and RXRs in male and female fertility and reproduction. PPAR Res 2008:637490
Froment P, Gizard F, Defever D, Staels B, Dupont J, Monget P (2006) Peroxisome proliferator-activated receptors in reproductive tissues: from gametogenesis to parturition. J Endocrinol 189:199–209
Fu J, Oveisi F, Gaetani S, Lin E, Piomelli D (2005) Oleoylethanolamide, an endogenous PPAR-alpha agonist, lowers body weight and hyperlipidemia in obese rats. Neuropharmacology 48:1147–1153
Fu H, Zhang J, Pan J, Zhang Q, Lu Y, Wen W, Lubet RA, Szabo E, Chen R, Wang Y, Chen DR, You M (2011) Chemoprevention of lung carcinogenesis by the combination of aerosolized budesonide and oral pioglitazone in A/J mice. Mol Carcinog 50:913–921
Fujita T, Sugiyama Y, Taketomi S, Sohda T, Kawamatsu Y, Iwatsuka H, Suzuoki Z (1983) Reduction of insulin resistance in obese and/or diabetic animals by 5-[4-(1-methylcyclohexyl methoxy)-benzyl]thiazolidine-2,4-dione (ADD-3878, U-63,287, ciglitazone), a new antidiabetic agent. Diabetes 32:804–810
Fujiwara T, Yoshioka S, Yoshioka T, Ushiyama I, Horikoshi H (1988) Characterization of a new oral antidiabetic agent CS-045: studies in kk and ob/ob mice and zucker fatty rats. Diabetes 37:1549–1558
Fukumoto K, Yano Y, Virgona N, Hagiwara H, Sato H, Senba H, Suzuki K, Asano R, Yamada K, Yano T (2005) Peroxisome proliferator-activated receptor delta as a molecular target to regulate lung cancer cell growth. FEBS Lett 579:3829–3836
Fulzele SV, Chatterjee A, Shaik MS, Jackson T, Ichite N, Singh M (2007) 15-Deoxy-Delta12,14-prostaglandin J2 enhances docetaxel anti-tumor activity against A549 and H460 non-small-cell lung cancer cell lines and xenograft tumors. Anticancer Drugs 18:65–78
Fyffe SA, Alphey MS, Buetow L, Smith TK, Ferguson MA, Sørensen MD, Björkling F, Hunter WN (2006) Recombinant human PPAR-beta/delta ligand-binding domain is locked in an activated conformation by endogenous fatty acids. J Mol Biol 356:1005–10013
Gazouli M, Yao ZX, Boujrad N, Corton JC, Culty M, Papadopoulos V (2002) Effect of peroxisome proliferators on Leydig cell peripheral-type benzodiazepine receptor gene expression, hormone-stimulated cholesterol transport, and steroidogenesis: role of the peroxisome proliferator-activator receptor alpha. Endocrinology 143:2571–2583
Gearing KL, Gottlicher M, Teboul M, Widmark E, Gustafson JA (1993) Interaction of peroxisome-proliferator-activated receptor and retinoid x-receptor. Proc Natl Acad Sci USA 90:1440–1444
Genini D, Catapano CV (2007) Block of nuclear receptor ubiquitination. A mechanism of ligand-dependent control of peroxisome proliferator-activated receptor delta activity. J Biol Chem 282:11776–11785
Genovese T, Cuzzocrea S, Di Paola R, Mazzon E, Mastruzzo C, Catalano P, Sortino M, Crimi N, Caputi AP, Thiemermann C, Vancheri C (2005) Effect of rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2 on bleomycin-induced lung injury. Eur Respir J 25:225–234
Genovese T, Mazzon E, Di Paola R, Muià C, Crisafulli C, Caputi AP, Cuzzocrea S (2006a) Role of endogenous and exogenous ligands for the peroxisome proliferator-activated receptor alpha in the development of bleomycin-induced lung injury. Shock 24:547–555
Genovese T, Mazzon E, Di Paola R, Muià C, Crisafulli C, Malleo G, Esposito E, Cuzzocrea S (2006b) Role of peroxisome proliferator-activated receptor-alpha in acute pancreatitis induced by cerulein. Immunology 118:559–570
Gerrits C, Bhattacharya M, Manthena S, Baran R, Perez A, Kupfer S (2007) A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes. Pharmacoepidemiol Drug Saf 16:1065–1071
Gervois P, Torra IP, Chinetti G, Grötzinger T, Dubois G, Fruchart JC, Fruchart-Najib J, Leitersdorf E, Staels B (1999) A truncated human peroxisome proliferator-activated receptor alpha splice variant with dominant negative activity. Mol Endocrinol 13:1535–1549
Ghazzi MN, Perez JE, Antonucci TK, Driscoll JH, Huang SM, Faja BW, Whitcomb RW (1997) Cardiac and glycemic benefits of troglitazone treatment in NIDDM. Diabetes 46:433–439
Ghosh M, Wang H, Ai Y, Romeo E, Luyendyk JP, Peters JM, Mackman N, Dey SK, Hla T (2007) COX-2 suppresses tissue factor expression via endocannabinoid-directed PPARdelta activation. J Exp Med 204:2053–2061
Gimble JM, Robinson CE, Wu X, Kelly KA, Rodriguez BR, Kliewer SA, Lehmann JM, Morris DC (1996) Peroxisome proliferator-activated receptor-gamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells. Mol Pharmacol 50:1087–1094
Girnun GD, Naseri E, Vafai SB, Qu L, Szwaya JD, Bronson R, Alberta JA, Spiegelman BM (2007) Synergy between PPARgamma ligands and platinum-based drugs in cancer. Cancer Cell 11:395–406
Girnun GD, Chen L, Silvaggi J, Drapkin R, Chirieac LR, Padera RF, Upadhyay R, Vafai SB, Weissleder R, Mahmood U, Naseri E, Buckley S, Li D, Force J, McNamara K, Demetri G, Spiegelman BM, Wong KK (2008) Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatin. Clin Cancer Res 14:6478–6486
Glatt H, Boeing H, Engelke C, Ma L, Kuhlow A, Pabel U, Pomplun D, Teubner W, Meinl W (2001) Human cytosolic sulphotransferases: genetics, characteristics, toxicological aspects. Mutat Res 482:27–40
Glinghammar B, Skogsberg J, Hamsten A, Ehrenborg E (2003) PPARdelta activation induces COX-2 gene expression and cell proliferation in human hepatocellular carcinoma cells. Biochem Biophys Res Commun 308:361–368
Gonzalez FJ, Shah YM (2008) PPARalpha: mechanism of species differences and hepatocarcinogenesis of peroxisome proliferators. Toxicology 246:2–8
Gonzalez IC, Lamar J, Iradier F, Xu Y, Winneroski LL, York J, Yumibe N, Zink R, Montrose-Rafizadeh C, Etgen GJ, Broderick CL, Oldham BA, Mantlo N (2007) Design and synthesis of a novel class of dual PPARgamma/delta agonists. Bioorg Med Chem Lett 17:1052–1055
Góth L, Rass P, Páy A (2004) Catalase enzyme mutations and their association with diseases. Mol Diagn 8:141–149
Goto T, Nagai H, Egawa K, Kim YI, Kato S, Taimatsu A, Sakamoto T, Ebisu S, Hohsaka T, Miyagawa H, Murakami S, Takahashi N, Kawada T (2011) Farnesyl pyrophosphate regulates adipocyte functions as an endogenous PPARγ agonist. Biochem J 438:111–119
Gottlicher M, Widmark E, Li Q, Gustafsson JA (1992) Fatty acids activate chimera of the clofibric acid-activated receptor and the glucocorticoid receptor. Proc Natl Acad Sci USA 89:4653–4657
Govindarajan R, Ratnasinghe L, Simmons DL, Siegel ER, Midathada MV, Kim L, Kim PJ, Owens RJ, Lang NP (2007) Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol 25:1476–1481
Goya K, Sumitani S, Xu X, Kitamura T, Yamamoto H, Kurebayashi S, Saito H, Kouhara H, Kasayama S, Kawase I (2004) Peroxisome proliferator-activated receptor alpha agonists increase nitric oxide synthase expression in vascular endothelial cells. Arterioscler Thromb Vasc Biol 24:658–663
Grabacka M, Plonka PM, Urbanska K, Reiss K (2006) Peroxisome proliferator-activated receptor alpha activation decreases metastatic potential of melanoma cells in vitro via down-regulation of akt. Clin Cancer Res 12:3028–3036
Graham D, Ouellet-Hellstrom R, MaCurdy T, Ali F, Sholley C, Worrall C, Kelman JA (2010) Risk of acutemyocardial infarction, stroke, heart failure, and death in elderly medicare patients treated with rosiglitazone or pioglitazone. JAMA 304:411–418
Gray JP, Burns KA, Leas TL, Perdew GH, Vanden Heuvel JP (2005) Regulation of peroxisome proliferator-activated receptor alpha by protein kinase C. Biochemistry 44:10313–10321
Gray JP, Davis JW 2nd, Gopinathan L, Leas TL, Nugent CA, Vanden Heuvel JP (2006) The ribosomal protein rpL11 associates with and inhibits the transcriptional activity of peroxisome proliferator-activated receptor-alpha. Toxicol Sci 89:535346
Greene ME, Blumberg B, McBride OW, Yi HF, Kronquist K, Kwan K, Hsieh L, Greene G, Nimer SD (1995) Isolation of the human peroxisome proliferator activated receptor gamma cDNA: expression in hematopoietic cells and chromosomal mapping. Gene Expr 4:281–299
Gregoire FM, Kersten S, Harrington W (2007) PPARS and obesity. PPAR Res 2007:78475
Gremlich S, Nolan C, Roduit R, Burcelin R, Peyot ML, Delghingaro-Augusto V, Desvergne B, Michalik L, Prentki M, Wahli W (2005) Pancreatic islet adaptation to fasting is dependent on peroxisome proliferator-activated receptor alpha transcriptional up-regulation of fatty acid oxidation. Endocrinology 146:375–382
Grimaldi PA (2007) Peroxisome proliferator activated receptors as sensors of fatty acids and derivatives. Cell Mol Life Sci 64:2459–2464
Grommes C, Landreth GE, Sastre M, Beck M, Feinstein DL, Jacobs AH, Schlegel U, Heneka MT (2006) Inhibition of in vivo glioma growth and invasion by peroxisome proliferator-activated receptor gamma agonist treatment. Mol Pharmacol 70:1524–1533
Gu BH, Baek KH (2009) Pro12Ala and His447His polymorphisms of PPAR-gamma are associated with polycystic ovary syndrome. Reprod Biomed Online 18:644–650
Guan Y (2004) Peroxisome proliferator-activated receptor family and its relationship to renal complications of the metabolic syndrome. J Am Soc Nephrol 15:2801–2815
Guan Y, Breyer MD (2001) Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease. Kidney Int 60:14–30
Guan Y, Zhang Y, Davis L, Breyer MD (1997) Expression of peroxisome proliferator-activated receptors in urinary tract of rabbits and humans. Am J Physiol Renal Physiol 273:F1013–F1022
Guan Y, Zhang Y, Schneider A, Davis L, Breyer RM, Breyer MD (2001) Peroxisome proliferator-activated receptor-gamma activity is associated with renal microvasculature. Am J Physiol Renal Physiol 281:F1036–F1046
Guan Y, Hao C, Cha DR, Rao R, Lu W, Kohan DE, Magnuson MA, Redha R, Zhang Y, Breyer MD (2005) Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med 11:861–866
Guerre-Millo M, Rouault C, Poulain P, André J, Poitout V, Peters JM, Gonzalez FJ, Fruchart JC, Reach G, Staels B (2001) PPAR-alpha-null mice are protected from high-fat diet-induced insulin resistance. Diabetes 50:2809–2814
Gulick T, Cresci S, Caira T, Moore DD, Kelly DP (1994) The peroxisome proliferator-activated receptor regulates mitochondrial fatty acid oxidative enzyme gene expression. Proc Natl Acad Sci USA 91:11012–11016
Gupta RA, Tan J, Krause WF, Geraci MW, Willson TM, Dey SK, DuBois RN (2000) Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. Proc Natl Acad Sci USA 97:13275–13280
Gupta RA, Polk DB, Krishna U, Israel DA, Yan F, DuBois RN, Peek RM Jr (2001) Activation of peroxisome proliferator-activated receptor gamma suppresses nuclear factor kappa B-mediated apoptosis induced by Helicobacter pylori in gastric epithelial cells. J Biol Chem 276:31059–31066
Gupta RA, Wang D, Katkuri S, Wang H, Dey SK, DuBois RN (2004) Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-delta accelerates intestinal adenoma growth. Nat Med 10:245–247
Guri AJ, Mohapatra SK, Horne WT 2nd, Hontecillas R, Bassaganya-Riera J (2010) The role of T cell PPAR gamma in mice with experimental inflammatory bowel disease. BMC Gastroenterol 10:60
Gutgesell A, Ringseis R, Brandsch C, Stangl GI, Hirche F, Eder K (2009) Peroxisome proliferator-activated receptor alpha and enzymes of carnitine biosynthesis in the liver are down-regulated during lactation in rats. Metabolism 58:226–232
Habib ZA, Havstad SL, Wells K, Divine G, Pladevall M, Williams LK (2010) Thiazolidinedione use and the longitudinal risk of fractures in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 95:592–600
Hall MG, Quignodon L, Desvergne B (2008) Peroxisome proliferator-activated receptor beta/delta in the brain: facts and hypothesis. PPAR Res 2008:780452
Ham SA, Kim HJ, Kim HJ, Kang ES, Eun SY, Kim GH, Park MH, Woo IS, Kim HJ, Chang KC, Lee JH, Seo HG (2010) PPARdelta promotes wound healing by up-regulating TGF-beta1-dependent or -independent expression of extracellular matrix proteins. J Cell Mol Med 14:1747–1759
Han SH, Quon MJ, Koh KK (2005) Beneficial vascular and metabolic effects of peroxisome proliferator-activated receptor-alpha activators. Hypertension 46:1086–1092
Han SJ, Kang ES, Hur KY, Kim HJ, Kim SH, Yun CO, Choi SE, Ahn CW, Cha BS, Kang Y, Lee HC (2008a) Rosiglitazone inhibits early stage of glucolipotoxicity-induced beta-cell apoptosis. Horm Res 70:165–173
Han S, Ritzenthaler JD, Zheng Y, Roman J (2008b) PPARbeta/delta agonist stimulates human lung carcinoma cell growth through inhibition of PTEN expression: the involvement of PI3K and NF-kappaB signals. Am J Physiol Lung Cell Mol Physiol 294:L1238–L1249
Han S, Ritzenthaler JD, Sun X, Zheng Y, Roman J (2009) Activation of peroxisome proliferator-activated receptor beta/delta induces lung cancer growth via peroxisome proliferator-activated receptor coactivator gamma-1alpha. Am J Respir Cell Mol Biol 40:325–331
Han L, Zhou R, Niu J, McNutt MA, Wang P, Tong T (2010) SIRT1 is regulated by a PPAR{gamma}-SIRT1 negative feedback loop associated with senescence. Nucleic Acid Res 2010:1–14
Hanley K, Jiang Y, Crumrine D, Bass NM, Appel R, Elias PM, Williams ML, Feingold KR (1997) Activators of the nuclear hormone receptors PPARalpha and FXR accelerate the development of the fetal epidermal permeability barrier. J Clin Invest 100:705–712
Hansmann G, Wagner RA, Schellong S, Perez VA, Urashima T, Wang L, Sheikh AY, Suen RS, Stewart DJ, Rabinovitch M (2007) Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator-activated receptor-gamma activation. Circulation 115:1275–1284
Hao CM, Redha R, Morrow J, Breyer MD (2002) Peroxisome proliferator-activated receptor delta activation promotes cell survival following hypertonic stress. J Biol Chem 277:21341–21345
Hara-Kuge S, Fujiki Y (2008) The peroxin Pex14p is involved in LC3-dependent degradation of mammalian peroxisomes. Exp Cell Res 314:3531–3541
Harman FS, Nicol CJ, Marin HE, Ward JM, Gonzalez FJ, Peters JM (2004) Peroxisome proliferator-activated receptor-delta attenuates colon carcinogenesis. Nat Med 10:481–483
Harmon GS, Dumlao DS, Ng DT, Barrett KE, Dennis EA, Dong H, Glass CK (2010) Pharmacological correction of a defect in PPAR-gamma signaling ameliorates disease severity in Cftr-deficient mice. Nat Med 16:313–318
Hart CM (2008) The role of PPARgamma in pulmonary vascular disease. J Investig Med 56:518–521
Haruna H, Shimizu T, Ohtsuka Y, Yarita Y, Fujii T, Kudo T, Yamashiro Y (2008) Expression of COX-1, COX-2, and PPAR-gamma in the gastric mucosa of children with Helicobacter pylori infection. Pediatr Int 50:1–6
Hase T, Yoshimura R, Mitsuhashi M, Segawa Y, Kawahito Y, Wada S, Nakatani T, Sano H (2002) Expression of peroxisome proliferator-activated receptors in human testicular cancer and growth inhibition by its agonists. Urology 60:542–547
Hashimoto Y, Nakahara K (2002) Improvement of asthma after administration of pioglitazone. Diabetes Care 25:401
Hau P, Kunz-Schughart L, Bogdahn U, Baumgart U, Hirschmann B, Weimann E, Muhleisen H, Ruemmele P, Steinbrecher A, Reichle A (2008) Low-dose chemotherapy in combination with COX-2 inhibitors and PPAR-gamma agonists in recurrent high-grade gliomas - a phase II study. Oncology 73:21–25
Hauser S, Adelmant G, Sarraf P, Wright HM, Mueller E, Spiegelman BM (2000) Degradation of the peroxisome proliferator-activated receptor gamma is linked to ligand-dependent activation. J Biol Chem 275:18527–18533
Hazra S, Peebles KA, Sharma S, Mao JT, Dubinett SM (2008) The role of PPARgamma in the cyclooxygenase pathway in lung cancer. PPAR Res 2008:790568
Heery DM, Kalkhoven E, Hoare S, Parker MG (1997) A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 387:733–736
Hellemans K, Michalik L, Dittie A, Knorr A, Rombouts K, De Jong J, Heirman C, Quartier E, Schuit F, Wahli W, Geerts A (2003) Peroxisome proliferator-activated receptor-beta signaling contributes to enhanced proliferation of hepatic stellate cells. Gastroenterology 124:184–201
Hellemans K, Kerckhofs K, Hannaert JC, Martens G, Van Veldhoven P, Pipeleers D (2007) Peroxisome proliferator-activated receptor alpha-retinoid X receptor agonists induce beta-cell protection against palmitate toxicity. FEBS J 274:6094–6105
Heneka MT, Landreth GE (2007) PPARs in the brain. Biochim Biophys Acta 1771:1031–1045
Henriksen K, Byrjalsen I, Qvist P, Beck-Nielsen H, Hansen G, Riis BJ, Perrild H, Svendsen OL, Gram J, Karsdal MA, Christiansen C (2011) Efficacy and safety of the PPARγ partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy. Diabetes Metab Res Rev 27:392–401
Hess R, Staubli W, Riess W (1965) Nature of the hepatomegalic effect produced by ethyl-chlorophenoxy-isobutyrate in the rat. Nature 208:856–858
Hirai T, Fukui Y, Motojima K (2007) PPARα agonists positively and negatively regulate the expression of several nutrient/drug transporters in mouse small intestine. Biol Pharm Bull 30:2185–2190
Hoetzel A, Dolinay T, Vallbracht S, Zhang Y, Kim HP, Ifedigbo E, Alber S, Kaynar AM, Schmidt R, Ryter SW, Choi AM (2008) Carbon monoxide protects against ventilator-induced lung injury via PPAR-gamma and inhibition of Egr-1. Am J Respir Crit Care Med 177:1223–1232
Holloway AC, Petrik JJ, Bruin JE, Gerstein HC (2008) Rosiglitazone prevents diabetes by increasing beta-cell mass in an animal model of type 2 diabetes characterized by reduced beta-cell mass at birth. Diabetes Obes Metab 10:763–771
Holness MJ, Smith ND, Greenwood GK, Sugden MC (2003) Acute (24 h) activation of peroxisome proliferator-activated receptor-alpha (PPARalpha) reverses high-fat feeding-induced insulin hypersecretion in vivo and in perifused pancreatic islets. J Endocrinol 177:197–205
Holness MJ, Greenwood GK, Smith ND, Sugden MC (2006) Peroxisome proliferator-activated receptor-alpha and glucocorticoids interactively regulate insulin secretion during pregnancy. Diabetes 55:3501–3508
Holness MJ, Smith ND, Greenwood GK, Sugden MC (2007) PPARalpha activation reverses adverse effects induced by high-saturated-fat feeding on pancreatic beta-cell function in late pregnancy. Am J Physiol Endocrinol Metab 292:E1087–E1094
Holst D, Luquet S, Nogueira V, Kristiansen K, Leverve X, Grimaldi PA (2003) Nutritional regulation and role of peroxisome proliferator-activated receptor delta in fatty acid catabolism in skeletal muscle. Biochim Biophys Acta 1633:43–50
Home P, Pocock S, Beck-Nielson H, Curtis PS, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ (2009) Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 373:2125–2135
Hontecillas R, Wannemeulher MJ, Zimmerman DR, Hutto DL, Wilson JH, Ahn DU, Bassaganya-Riera J (2002) Nutritional regulation of porcine bacterial-induced colitis by conjugated linoleic acid. J Nutr 132:2019–2027
Horio M, Gottesman M, Pastan I (1988) ATP-dependent transport of vinblastine in vesicles from human multidrug-resistant cells. Proc Natl Acad Sci USA 85:3580–3584
Hsu MC, Huang CC, Chang HC, Hu TH, Hung WC (2008) Overexpression of Jab1 in hepatocellular carcinoma and its inhibition by peroxisome proliferator-activated receptor{gamma} ligands in vitro and in vivo. Clin Cancer Res 14:4045–4052
Huang Q, Alvares K, Chu R, Bradfield CA, Reddy JK (1994) Association of peroxisome proliferator activated receptor and Hsp 72. J Biol Chem 269:8493–8497
Huguenin GV, Rosa G (2010) The Ala allele in the PPAR-gamma2 gene is associated with reduced risk of type 2 diabetes mellitus in Caucasians and improved insulin sensitivity in overweight subjects. Br J Nutr 104:488–497
Huin C, Corriveau L, Bianchi A, Keller JM, Collet P, Krémarik-Bouillaud P, Domenjoud L, Bécuwe P, Schohn H, Ménard D, Dauça M (2000) Differential expression of peroxisome proliferator-activated receptors (PPARs) in the developing human fetal digestive tract. J Histochem Cytochem 48:603–611
Hummasti S, Tontonoz P (2006) The peroxisome proliferator-activated receptor N-terminal domain controls subtype-selective gene expression and adipogenesis. Mol Endocrinol 20:1261–1275
Huybrechts S, Van Veldhoven P, Brees C, Mannaerts GP, Los GV, Fransen M (2009) Peroxisome dynamics in cultured mammalian cells. Traffic 10:1722–1733
Hwang KR, Choi YM, Kim JM, Lee GH, Kim JJ, Chae SJ, Moon SY (2010) Association of peroxisome proliferator-activated receptor-gamma 2 Pro12Ala polymorphism with advanced-stage endometriosis. Am J Reprod Immunol 64:333–338
Ijpenberg A, Jeanin E, Wahli W, Desvergne B (1997) Polrity and specific sequence requirements of peroxisome proliferator-activated receptor heterodimer binding to DNA. A functional analysis of the malic enzyme PPAR response element. J Biol Chem 272:20108–20117
Inamoto T, Shah JB, Kamat AM (2009) Friend or foe? Role of peroxisome proliferator-activated receptor-gamma in human bladder cancer. Urol Oncol 27:585–591
Inoue K, Kawahito Y, Tsubouchi Y, Yamada R, Kohno M, Hosokawa Y, Katoh D, Bishop-Bailey D, Hla T, Sano H (2001) Expression of peroxisome proliferator-activated receptor (PPAR)-gamma in human lung cancer. Anticancer Res 21:2471–2476
Irukayama-Tomobe Y, Miyauchi T, Sakai S, Kasuya Y, Ogata T, Takanashi M, Iemitsu M, Sudo T, Goto K, Yamaguchi I (2004) Endothelin-1-induced cardiac hypertrophy is inhibited by activation of peroxisome proliferator-activated receptor-alpha partly via blockade of c-Jun NH2-terminal kinase pathway. Circulation 109:904–910
Islinger M, Cardoso MJR, Schrader M (2010) Be different, the diversity of peroxisomes in the animal kingdom. Biochim Biophys Acta 1803:881–897
Islinger M, Grille S, Fahimi HD, Schrader M (2012) The peroxisome: an update on mysteries. Histochem Cell Biol 137:547–574
Issemann I, Green S (1990) Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347:645–650
Jackson SM, Demer LL (2000) Peroxisome proliferator-activated receptor activators modulate the osteoblastic maturation of MC3T3-E1 preosteoblasts. FEBS Lett 471:119–124
Jaster R, Lichte P, Fitzner B, Brock P, Glass A, Karopka T, Gierl L, Koczan D, Thiesen HJ, Sparmann G, Emmrich J, Liebe S (2005) Peroxisome proliferator-activated receptor gamma overexpression inhibits pro-fibrogenic activities of immortalized rat pancreatic stellate cells. J Cell Mol Med 9:670–682
Jaudszus A, Krokowski M, Möckel P, Darcan Y, Avagyan A, Matricardi P, Jahreis G, Hamelmann E (2008) Cis-9, trans-11-conjugated linoleic acid inhibits allergic sensitization and airway inflammation via a PPARgamma-related mechanism in mice. J Nutr 138:1336–1342
Jguirim-Souissi I, Jelassi A, Hrira Y, Najah M, Slimani A, Addad F, Hassine M, Hamda KB, Maatouk F, Rouis M, Slimane MN (2010) +294T/C polymorphism in the PPAR-delta gene is associated with risk of coronary artery disease in normolipidemic Tunisians. Genet Mol Res 9:1326–1333
Jia D, Otsuki M (2003) Bezafibrate, a peroxisome proliferator-activated receptor (PPAR)-alpha activator, prevents pancreatic degeneration in obese and diabetic rats. Pancreas 26:286–291
Jiang Y, Kim P, Elias P, Feingold K (2005) LXR and PPAR activators stimulate cholesterol sulfotransferase type 2 isoform 1b in human keratinocytes. J Lipid Res 46:2657–2666, 10.1194/jlr.M500235-JLR200
Jiang YJ, Barish G, Lu B, Evans RM, Crumrine D, Schmuth M, Elias PM, Feingold KR (2010) PPARδ activation promotes stratum corneum formation and epidermal permeability barrier development during late gestation. J Invest Dermatol 130:511–519
Johnson E, Palmer C, Griffin K, Hsu M (1996) Role of the peroxisome proliferator-activated receptor in cytochrome P4504A gene regulation. EMBO J 10:1241–1248
Johnson W, Harris SE, Starr JM, Whalley LJ, Deary IJ (2008) PPARG Pro12Ala genotype and risk of cognitive decline in elders? Maybe with diabetes. Neurosci Lett 434:450–455
Jones JM, Morrell JC, Gould SJ (2004) PEX19 is a predominantly cytosolic chaperone and import receptor for class 1 peroxisomal membrane proteins. J Cell Biol 164:57–67
Jucker BM, Doe CP, Schnackenberg CG, Olzinski AR, Maniscalco K, Williams C, Hu TC, Lenhard SC, Costell M, Bernard R, Sarov-Blat L, Steplewski K, Willette RN (2007) PPARdelta activation normalizes cardiac substrate metabolism and reduces right ventricular hypertrophy in congestive heart failure. J Cardiovasc Pharmacol 50:25–34
Juge-Aubry CE, Gorla-Bajszczak A, Pernin A, Lemberger T, Wahli W, Burger AG, Meier CA (1995) Peroxisome proliferator-activated receptor mediates cross-talk with thyroid hormone receptor by competition for retinoid X receptor. Possible role of a leucine zipper-like heptad repeat. J Biol Chem 270:18117–18122
Juge-Aubry CE, Kuenzli S, Sanchez JC, Hochstrasser D, Meier CA (2001) Peroxisomal bifunctional enzyme binds and activates the activation function-1 region of the peroxisome proliferator-activated receptor alpha. Biochem J 553:253–258
Jung K, Tanaka A, Fujita H, Matsuda A, Oida K, Karasawa K, Okamoto N, Ohmori K, Jee Y, Shin T, Matsuda H (2011) Peroxisome proliferator-activated receptor γ-mediated suppression of dendritic cell function prevents the onset of atopic dermatitis in NC/Tnd mice. J Allergy Clin Immunol 127:420–429
Juurlink D, Gomes T, Lipscombe L, Austin PC, Hux JE, Mamdani MM (2009) Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study. BMJ 339:b2942
Kahn S, Haffner S, Heise M, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O’Neill MC, Zinman B, Viberti G (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355:2427–2443
Karam WG, Ghanayem BI (1997) Induction of replicative DNA synthesis and PPAR alpha-dependent gene transcription by Wy-14,643 in primary rat hepatocyte and non-parenchymal cell co-cultures. Carcinogenesis 18:2077–2083
Karnik P, Tekeste Z, McCormick TS, Gilliam AC, Price VH, Cooper KD, Mirmirani P (2009) Hair follicle stem cell-specific PPARgamma deletion causes scarring alopecia. J Invest Dermatol 129:1243–1257
Kassouf W, Chintharlapalli S, Abdelrahim M, Nelkin G, Safe S, Kamat AM (2006) Inhibition of bladder tumor growth by 1,1-bis(3'-indolyl)-1-(p-substituted phenyl) methanes: a new class of peroxisome proliferator-activated receptor gamma agonists. Cancer Res 66:412–418
Kawai T, Masaki T, Doi S, Arakawa T, Yokoyama Y, Doi T, Kohno N, Yorioka N (2009) PPAR-gamma agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-beta. Lab Invest 89:47–58
Keppler D, Kartenbeck J (1996) The canalicular conjugate export pump encoded by the cmrp/cmoat gene. Prog Liver Dis 14:55–67
Kersten S, Seydoux J, Peters JM, Gonzalez FJ, Desvergne B, Wahli W (1999) Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. J Clin Invest 103:1489–1498
Keshamouni VG, Arenberg DA, Reddy RC, Newstead MJ, Anthwal S, Standiford TJ (2005) PPAR-gamma activation inhibits angiogenesis by blocking ELR+CXC chemokine production in non-small cell lung cancer. Neoplasia 7:294–301
Ketsawatsomkron P, Pelham CJ, Groh S, Keen HL, Faraci FM, Sigmund CD (2010) Does peroxisome proliferator-activated receptor-gamma (PPAR gamma) protect from hypertension directly through effects in the vasculature? J Biol Chem 285:9311–9316
Kim DJ, Akiyama TE, Harman FS, Burns AM, Shan W, Ward JM, Kennett MJ, Gonzalez FJ, Peters JM (2004a) Peroxisome proliferator-activated receptor beta (delta)-dependent regulation of ubiquitin C expression contributes to attenuation of skin carcinogenesis. J Biol Chem 279:23719–23727
Kim M, Wang S, Shen Z, Kochansky C, Strauss J, Franklin R, Vincent S (2004b) Differences in the pharmacokinetics of peroxisome proliferator-activated receptor agonists in genetically obese Zucker and Sprague-Dawley rats: implications of decreased glucuronidation in obese Zucker rats. Drug Metab Dispos 32:909–914
Kim DJ, Bility MT, Billin AN, Willson TM, Gonzalez FJ, Peters JM (2006) PPARbeta/delta selectively induces differentiation and inhibits cell proliferation. Cell Death Differ 13:53–60
Kim EK, Kwon KB, Koo BS, Han MJ, Song MY, Song EK, Han MK, Park JW, Ryu DG, Park BH (2007a) Activation of peroxisome proliferator-activated receptor-gamma protects pancreatic beta-cells from cytokine-induced cytotoxicity via NF kappaB pathway. Int J Biochem Cell Biol 39:1260–1275
Kim KR, Choi HN, Lee HJ, Baek HA, Park HS, Jang KY, Chung MJ, Moon WS (2007b) A peroxisome proliferator-activated receptor gamma antagonist induces vimentin cleavage and inhibits invasion in high-grade hepatocellular carcinoma. Oncol Rep 18:825–832
Kim HS, Noh JH, Hong SH, Hwang YC, Yang TY, Lee MS, Kim KW, Lee MK (2008a) Rosiglitazone stimulates the release and synthesis of insulin by enhancing GLUT-2, glucokinase and BETA2/NeuroD expression. Biochem Biophys Res Commun 367:623–629
Kim P, Hailey D, Mullen R, Lippincott-Schwartz J (2008b) Ubiquitin signals autophagic degradation of cytosolic proteins and peroxisomes. Proc Nat Acad Sci USA 105:20567–20574
Kippenberger S, Loitsch SM, Grundmann-Kollmann M, Simon S, Dang TA, Hardt-Weinelt K, Kaufmann R, Bernd A (2001) Activators of peroxisome proliferator-activated receptors protect human skin from ultraviolet-B-light-induced inflammation. J Invest Dermatol 117:1430–1436
Kliewer SA, Umesono K, Noonan DJ, Heyman RA, Evans RM (1992) Convergence of 9-Cis retinoic acid and peroxisome proliferator signaling pathways through heterodimer formation of their receptors. Nature 358:771–774
Kliewer S, Sundseth S, Jones S, Brown P, Wisely GB, Koble C, Devchand P, Wahli W, Willson T, Lenhard J, Lehman J (1997) Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ. Proc Natl Acad Sci USA 94:4318–4323
Kliewer SA, Xu HE, Lambert MH, Willson TM (2001) PPAR from gene to physiology. Recent Prog Horm Res 56:239–263
Koch M, Rett K, Maerker E, Volk A, Haist K, Deninger M, Rettig A, Renn W, Häring HU (2000) The silent PPARgamma exon 6 CAC(His) CAT(His) polymorphism does not affect the plasma leptin levels in a collective of first degree relatives of type 2 diabetes patients from South West Germany. Endocrinol Diabetes 108:341–346
Koga H, Sakisaka S, Harada M, Takagi T, Hanada S, Taniguchi E, Kawaguchi T, Sasatomi K, Kimura R, Hashimoto O, Ueno T, Yano H, Kojiro M, Sata M (2001) Involvement of p21(WAF1/Cip1), p27(Kip1), and p18(INK4c) in troglitazone-induced cell-cycle arrest in human hepatoma cell lines. Hepatology 33:1087–1097
Koga H, Harada M, Ohtsubo M, Shishido S, Kumemura H, Hanada S, Taniguchi E, Yamashita K, Kumashiro R, Ueno T, Sata M (2003) Troglitazone induces p27Kip1-associated cell-cycle arrest through down-regulating Skp2 in human hepatoma cells. Hepatology 37:1086–1096
Koga H, Selvendiran K, Sivakumar R, Yoshida T, Torimura T, Ueno T, Sata M (2011) PPARγ potentiates anticancer effects of gemcitabine on human pancreatic cancer cells. Int J Oncol 40:679–685
Koh EH, Kim MS, Park JY, Kim HS, Youn JY, Park HS, Youn JH, Lee KU (2003) Peroxisome proliferator-activated receptor (PPAR)-alpha activation prevents diabetes in OLETF rats: comparison with PPAR-gamma activation. Diabetes 52:2331–2337
Koh K, Xie H, Yu AM, Jeong H (2011) Altered cytochrome P450 expression in mice during pregnancy. Drug Metab Dispos 39:165–169
Koivisto AM, Helisalmi S, Pihlajamaki J, Hiltunen M, Koivisto K, Moilanen L, Kuusisto J, Helkala EL, Hanninen T, Kervinen K, Kesaniemi YA, Laakso M, Soininen H (2006) Association analysis of peroxisome proliferator-activated receptor gamma polymorphisms and late onset alzheimer’s disease in the Finnish population. Dement Geriatr Cogn Disord 22:449–453
Kojima K, Shimada T, Mitobe Y, Yoshiura K, Hiraishi H, Terano A (2002) Effect of PPARgamma ligands on the viability of gastric epithelial cells. Aliment Pharmacol Ther 16(2):67–73
Kok T, Bloks V, Wolters H, Havinga R, Jansen P, Staels B, Kuipers F (2003) Peroxisome proliferator-activated receptor alpha (PPARalpha)-mediated regulation of multidrug resistance 2 (Mdr2) expression and function in mice. Biochem J 369:539347
Kömüves LG, Hanley K, Man MQ, Elias PM, Williams ML, Feingold KR (2000) Keratinocyte differentiation in hyperproliferative epidermis: topical application of PPARalpha activators restores tissue homeostasis. J Invest Dermatol 115:361–367
Konturek PC, Brzozowski T, Kania J, Kukharsky V, Bazela K, Kwiecien S, Harsch I, Konturek SJ, Hahn EG (2003) Pioglitazone, a specific ligand of the peroxisome proliferator-activated receptor gamma reduces gastric mucosal injury induced by ischaemia/ reperfusion in rat. Scand J Gastroenterol 38:468–476
Konturek PC, Brzozowski T, Burnat G, Szlachcic A, Koziel J, Kwiecien S, Konturek SJ, Harsch IA (2010) Gastric ulcer healing and stress-lesion preventive properties of pioglitazone are attenuated in diabetic rats. J Physiol Pharmacol 61:429–436
Kopelovich L, Fay JR, Glazer RI, Crowell JA (2002) Peroxisome proliferator-activated receptor modulators as potential chemopreventive agents. Mol Cancer Ther 1:357–363
Koytak ES, Mizrak D, Bektaş M, Verdi H, Arslan Ergül A, Idilman R, Cinar K, Yurdaydin C, Ersõz S, Karayalçin K, Uzunalimoğlu O, Bozkaya H (2008) PPAR-alpha L162V polymorphism in human hepatocellular carcinoma. Turk J Gastroenterol 19:245–249
Kristiansen G, Jacob J, Buckendahl AC, Grützmann R, Alldinger I, Sipos B, Klöppel G, Bahra M, Langrehr JM, Neuhaus P, Dietel M, Pilarsky C (2006) Peroxisome proliferator-activated receptor gamma is highly expressed in pancreatic cancer and is associated with shorter overall survival times. Clinical Cancer Res 12:6444–6451
Kuenzli S, Saurat JH (2001a) Effect of topical PPARbeta/delta and PPARgamma agonists on plaque psoriasis. A pilot study. Dermatology 206:252–256
Kuenzli S, Saurat JH (2001b) Peroxisome proliferator-activated receptors in cutaneous biology. Br J Dermatology 149:229–236
Kulkarni AA, Thatcher TH, Olsen KC, Maggirwar SB, Phipps RP, Sime PJ (2011) PPAR-γ ligands repress TGFβ-induced myofibroblast differentiation by targeting the PI3K/Akt pathway: implications for therapy of fibrosis. PLoS One 6(1):e15909
Kumei S, Motomura W, Yoshizaki T, Takakusaki K, Okumura T (2009) Troglitazone increases expression of E-cadherin and claudin 4 in human pancreatic cancer cells. Biochem Biophys Res Commun 380:414–419
Kung J, Henry R (2012) Thiazolidinedione safety. Expert Opin Drug Saf 11:565–579
Lakatos HF, Thatcher TH, Kottmann RM, Garcia TM, Phipps RP, Sime PJ (2007) The role of PPARs in lung fibrosis. PPAR Res 2007:71323
Lake BG, Gray TJ (1985) Species differences in hepatic peroxisome proliferation. Biochem Soc Trans 13:859–861
Lalloyer F, Staels B (2010) Fibrates, glitazones, and peroxisome proliferator-activated receptors. Arterioscler Thromb Vasc Biol 30:894–899
Lalloyer F, Vandewalle B, Percevault F, Torpier G, Kerr-Conte J, Oosterveer M, Paumelle R, Fruchart JC, Kuipers F, Pattou F, Fiévet C, Staels B (2006) Peroxisome proliferator-activated receptor alpha improves pancreatic adaptation to insulin resistance in obese mice and reduces lipotoxicity in human islets. Diabetes 55:1605–1613
Lalwani ND, Fahl WE, Reddy JK (1983) Detection of a nafenopin binding protein in rat liver cytosol associated with induction of peroxisome proliferation by hypolipidemic compounds. Biochem Biophys Res Commun 116:388–393
Lalwani ND, Alvarres K, Reddy MK, Reddy MN (1987) Peroxisome proliferator-binding protein: identification and partial characterization of nafenopin-, clofibric acid-, and ciprofibrate-binding proteins from rat liver. Proc Natl Acad Sci USA 84:5242–5246
Lambrot R, Muczynski V, Lécureuil C, Angenard G, Coffigny H, Pairault C, Moison D, Frydman R, Habert R, Rouiller-Fabre V (2009) Phthalates impair germ cell development in the human fetal testis in vitro without change in testosterone production. Environ Health Persp 117:32–37
Larter CZ, Yeh MM, Cheng J, Williams J, Brown S, dela Pena A, Bell-Anderson KS, Farrell GC (2008) Activation of peroxisome proliferator-activated receptor alpha by dietary fish oil attenuates steatosis, but does not prevent experimental steatohepatitis because of hepatic lipoperoxide accumulation. J Gastroenterol Hepatol 23:267–275
Latini G, Scoditti E, Verrotti A, De Felice C, Massaro M (2008) Peroxisome proliferator-activated receptors as mediators of phthalate-induced effects in the male and female reproductive tract: epidemiological and experimental evidence. PPAR Res 2008:359267
Law RE, Meehan WP, Xi XP, Graf K, Wuthrich DA, Coats W, Faxon D, Hsueh WA (1996) Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest 98:1897–1905
Lawrence J, Wollengerg G, DeLuca J (2001) Tumor necrosis factor alpha is not required for Wy-14,643-induced cell proliferation. Carcinogenesis 22:381–386
Lee SS, Pineau T, Drago J, Lee EJ, Owens JW, Kroetz DL, Fernandez-Salguero PM, Westphal H, Gonzalez FJ (1995) Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol 15:3012–3022
Lee KS, Park SJ, Kim SR, Min KH, Jin SM, Lee HK, Lee YC (2006a) Modulation of airway remodeling and airway inflammation by peroxisome proliferator-activated receptor gamma in a murine model of toluene diisocyanate-induced asthma. J Immunol 177:5248–5257
Lee CH, Olson P, Hevener A, Mehl I, Chong LW, Olefsky JM, Gonzalez FJ, Ham J, Kang H, Peters JM, Evans RM (2006b) PPARdelta regulates glucose metabolism and insulin sensitivity. Proc Natl Acad Sci USA 103:3444–3449
Lee SY, Kang EJ, Hur GY, Jung KH, Jung HC, Lee SY, Kim JH, Shin C, In KH, Kang KH, Yoo SH, Shim JJ (2006c) Peroxisome proliferator-activated receptor-gamma inhibits cigarette smoke solution-induced mucin production in human airway epithelial (NCI-H292) cells. Am J Physiol Lung Cell Mol Physiol 291:L84–L90
Lee JS, Choi YM, Kang HY (2007) PPAR-gamma agonist, ciglitazone, increases pigmentation and migration of human melanocytes. Exp Dermatol 16:118–123
Lee JH, Woo JH, Woo SU, Kim KS, Park SM, Joe EH, Jou I (2008) The 15-deoxy-delta 12,14-prostaglandin J2 suppresses monocyte chemoattractant protein-1 expression in IFN-gamma-stimulated astrocytes through induction of MAPK phosphatase-1. J Immunol 181:8642–8864
Lefebvre AM, Chen I, Desreumaux P, Najib J, Fruchart JC, Geboes K, Briggs M, Heyman R, Auwerx J (1998) Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nat Med 4:1053–1057
Leibowitz MD, Fiévet C, Hennuyer N, Peinado-Onsurbe J, Duez H, Bergera J, Cullinan CA, Sparrow CP, Baffic J, Berger GD, Santini C, Marquis RW, Tolman RL, Smith RG, Moller DE, Auwerx J (2000) Activation of PPARdelta alters lipid metabolism in db/db mice. FEBS Lett 473:333–336
Letavernier E, Perez J, Joye E, Bellocq A, Fouqueray B, Haymann JP, Heudes D, Wahli W, Desvergne B, Baud L (2005) Peroxisome proliferator-activated receptor beta/delta exerts a strong protection from ischemic acute renal failure. J Am Soc Nephrol 16:2395–2402
Lewis JD, Lichtenstein GR, Deren JJ, Sands BE, Hanauer SB, Katz JA, Lashner B, Present DH, Chuai S, Ellenberg JH, Nessel L, Wu GD (2008) Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial. Gastroenterology 134:688–695
Li D, Kang Q, Wang DM (2007) Constitutive coactivator of peroxisome proliferator-activated receptor (PPARgamma), a novel coactivator of PPARgamma that promotes adipogenesis. Mol Endocrinol 21:2320–2333
Li CB, Li XX, Chen YG, Zhang C, Zhang MX, Zhao XQ, Hao MX, Hou XY, Gong ML, Zhao YX, Bu PL, Zhang Y (2008) Effects and mechanisms of PPARalpha activator fenofibrate on myocardial remodelling in hypertension. J Cell Mol Med 13:4444–4452
Li MY, Yuan H, Ma LT, Kong AW, Hsin MK, Yip J, Underwood MJ, Chen GG (2010a) Roles of PPAR{alpha} and PPAR{gamma} in the development of non-small cell lung cancer. Am J Respir Cell Mol Biol 43:674–683
Li H, Cui R, Cai H, Wu G, Lv Z, Sheng C, Cheng X, Li F, Yu Y (2010b) The effect of thiazolidinediones on bone mineral density in Chinese older patients with type 2 diabetes. J Bone Miner Metab 28:77–81
Liang F, Wang F, Zhang S, Gardner DG (2003) Peroxisome proliferator activated receptor (PPAR)alpha agonists inhibit hypertrophy of neonatal rat cardiac myocytes. Endocrinology 144:4187–4194
Liao SY, Zeng ZR, Leung WK, Zhou SZ, Chen B, Sung JJ, Hu PJ (2006) Peroxisome proliferator-activated receptor-gamma Pro12Ala polymorphism, Helicobacter pylori infection and non-cardia gastric carcinoma in Chinese. Aliment Pharmacol Ther 23:289–294
Lichtor T, Spagnolo A, Glick RP, Feinstein DL (2008) PPAR-gamma thiazolidinedione agonists and immunotherapy in the treatment of brain tumors. PPAR Res 2008:547470
Lim H, Dey SK (2000) PPAR delta functions as a prostacyclin receptor in blastocyst implantation. Trends Endocrinol Metab 11:137–142
Lim H, Gupta R, Ma W-G, Paria B, Moller D, Morrow J, DuBois R, Trzaskos J, Dey S (1999) Cyclooxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARγ. Genes Dev 13:1561–1574
Lin Q, Fang LP, Zhou WW, Liu XM (2010) Rosiglitazone inhibits migration, proliferation, and phenotypic differentiation in cultured human lung fibroblasts. Exp Lung Res 36:120–128
Lipscombe L, Gomes T, Levesque L, Hux JE, Juurlink DN, Alter DA (2007) Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA 298:2634–2643
Little J, Drake R, Vonk R, Kuipers F, Lester R, Radominska A (1995) Characterization of human liver microsomal UDP-glycosyltransferases using photoaffinity analogs. J Pharmacol Exp Ther 273:1551–1559
Liu MH, Li J, Shen P, Husna B, Tai ES, Yong EL (2008) A natural polymorphism in peroxisome proliferator-activated receptor-alpha hinge region attenuates transcription due to defective release of nuclear receptor corepressor from chromatin. Mol Endocrinol 22:1078–1092
Liu SN, Liu Q, Li LY, Huan Y, Sun SJ, Shen ZF (2011a) Long-term fenofibrate treatment impaired glucose-stimulated insulin secretion and up-regulated pancreatic NF-kappa B and iNOS expression in monosodium glutamate-induced obese rats: is that a latent disadvantage? J Transl Med 9:176
Liu J, Wang P, Luo J, Huang Y, He L, Yang H, Li Q, Wu S, Zhelyabovska O, Yang Q (2011b) Peroxisome proliferator-activated receptor β/δ activation in adult hearts facilitates mitochondrial function and cardiac performance under pressure-overload condition. Hypertension 57:223–230
Lollingshead HE, Killins RL, Borland MG, Girroir EE, Billin AN, Willson TM, Sharma AK, Amin S, Gonzalez FJ, Peters JM (2007) Peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) ligands do not potentiate growth of human cancer cell lines. Carcinogenesis 28:2641–2649
Lu J, Imamura K, Nomura S, Mafune K, Nakajima A, Kadowaki T, Kubota N, Terauchi Y, Ishii G, Ochiai A, Esumi H, Kaminishi M (2005) Chemopreventive effect of peroxisome proliferator-activated receptor gamma on gastric carcinogenesis in mice. Cancer Res 65:4769–4774
Lu M, Sarruf DA, Talukdar S, Sharma S, Li P, Bandyopadhyay G, Nalbandian S, Fan W, Gayen JR, Mahata SK, Webster NJ, Schwartz MW, Olefsky JM (2011) Brain PPAR-γ promotes obesity and is required for the insulin-sensitizing effect of thiazolidinediones. Nat Med 17:618–622
Lubet RA, Fischer SM, Steele VE, Juliana MM, Desmond R, Grubbs CJ (2008) Rosiglitazone, a PPAR gamma agonist: potent promoter of hydroxybutyl (butyl) nitrosamine-induced urinary bladder cancers. Int J Cancer 123:2254–2259
Luconi M, Cantini G, Serio M (2010) Peroxisome proliferator-activated receptor gamma (PPARgamma): is the genomic activity the only answer? Steroids 75:585–594
Lüdtke A, Buettner J, Wu W, Muchir A, Schroeter A, Zinn-Justin S, Spuler S, Schmidt HH, Worman HJ (2007) Peroxisome proliferator-activated receptor-gamma C190S mutation causes partial lipodystrophy. J Clin Endocrinol Metabol 92:2248–2255
Lundell K, Thulin P, Hamsten A, Ehrenborg E (2007) Alternative splicing of human peroxisome proliferator-activated receptor delta (PPAR delta): effects on translation efficiency and trans-activation ability. BMC Mol Biol 8:70
Luo Y, Yin W, Signore AP, Zhang F, Hong Z, Wang S, Graham SH, Chen J (2006) Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. J Neurochem 97:435–448
Lupi R, Del Guerra S, Marselli L, Bugliani M, Boggi U, Mosca F, Marchetti P, Del Prato S (2004) Rosiglitazone prevents the impairment of human islet function induced by fatty acids: evidence for a role of PPARgamma2 in the modulation of insulin secretion. Am J Physiol Endocrinol Metab 286:E560–E567
Lyon CM, Klinge DM, Do KC, Grimes MJ, Thomas CL, Damiani LA, March TH, Stidley CA, Belinsky SA (2009) Rosiglitazone prevents the progression of preinvasive lung cancer in a murine model. Carcinogenesis 30:2095–2099
Lytle C, Tod TJ, Vo KT, Lee JW, Atkinson RD, Straus DS (2005) The peroxisome proliferator-activated receptor gamma ligand rosiglitazone delays the onset of inflammatory bowel disease in mice with interleukin 10 deficiency. Inflamm Bowel Dis 11:231–243
Madrigal JL, Kalinin S, Richardson JC, Feinstein DL (2007) Neuroprotective actions of noradrenaline: effects on glutathione synthesis and activation of peroxisome proliferator activated receptor delta. J Neurochem 103:2092–2101
Maeda T, Wakasawa T, Funabashi M, Fukushi A, Fujita M, Motojima K, Tamai I (2008) Regulation of Octn2 transporter (SLC22A5) by peroxisome proliferator activated receptor alpha. Biol Pharm Bull 31:1230–1236
Maejima Y, Okada H, Haraguchi G, Onai Y, Kosuge H, Suzuki J, Isobe M (2011) Telmisartan, a unique ARB, improves left ventricular remodeling of infarcted heart by activating PPAR gamma. Lab Invest 91:932–944
Maher J, Aleksunes L, Dieter M, Tanaka Y, Peters J, Manautou JE, Klaassen C (2008) Nrf2- and PPAR alpha-mediated regulation of hepatic Mrp transporters after exposure to perfluorooctanoic acid and perfluorodecanoic acid. Toxicol Sci 106:319–328
Maiuri L, Luciani A, Giardino I, Raia V, Villella VR, D'Apolito M, Pettoello-Mantovani M, Guido S, Ciacci C, Cimmino M, Cexus ON, Londei M, Quaratino S (2008) Tissue transglutaminase activation modulates inflammation in cystic fibrosis via PPARgamma down-regulation. J Immunol 180:7697–7705
Maliepaard M, Scheffer G, Faneyte I, van Gastelen M, Pijnenborg A, Schinkel A, van De Vijver M, Scheper R, Schellens JH (2001) Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 61:3458–3464
Man MQ, Choi EH, Schmuth M, Crumrine D, Uchida Y, Elias PM, Holleran WM, Feingold KR (2006) Basis for improved permeability barrier homeostasis induced by PPAR and LXR activators: liposensors stimulate lipid synthesis, lamellar body secretion, and post-secretory lipid processing. J Invest Dermatol 126:386–392
Man MQ, Barish GD, Schmuth M, Crumrine D, Barak Y, Chang S, Jiang Y, Evans RM, Elias PM, Feingold KR (2008) Deficiency of PPARbeta/delta in the epidermis results in defective cutaneous permeability barrier homeostasis and increased inflammation. J Invest Dermatol 128:370–377
Manautou J, de Waart D, Kunne C, Zelcer N, Goedken M, Borst P, Elferink R (2005) Altered disposition of acetaminophen in mice with a disruption of the Mrp3 gene. Hepatology 42:1091–1098
Mandard S, Müller M, Kersten S (2004) Peroxisome proliferator-activated receptor alpha target genes. Cell Mol Life Sci 61:393–416
Mannucci E, Monami M, Di Bari M, Lamanna C, Gori F, Gensini GF, Marchionni N (2010) Cardiac safety profile of rosiglitazone: a comprehensive meta-analysis of randomized clinical trials. Int J Cardiol 143:135–140
Mansén A, Guardiola-Diaz H, Rafter J, Branting C, Gustafsson JA (1996) Expression of the peroxisome proliferator-activated receptor (PPAR) in the mouse colonic mucosa. Biochem Biophys Res Commun 222:844–851
Mao Z, Ong AC (2009) Peroxisome proliferator-activated receptor gamma agonists in kidney disease–future promise, present fears. Nephron Clin Pract 112:c230–c241
Mao-Qiang M, Fowler AJ, Schmuth M, Lau P, Chang S, Brown BE, Moser AH, Michalik L, Desvergne B, Wahli W, Li M, Metzger D, Chambon PH, Elias PM, Feingold KR (2004) Peroxisome-proliferator-activated receptor (PPAR)-gamma activation stimulates keratinocyte differentiation. J Invest Dermatol 123:305–312
Margolis D, Hoffstad O, Strom B (2008) Association between serious ischemic cardiac outcomes and medications used to treat diabetes. Pharmacoepidemiol Drug Saf 17:753–759
Marrapodi M, Chiang J (2000) Peroxisome proliferator-activated receptor alpha (PPARalpha) and agonist inhibit cholesterol 7alpha-hydroxylase gene (CYP7A1) transcription. J Lipid Res 41:514–520
Marsman DS, Cattley RC, Conway JG, Popp JA (1988) Relationship of hepatic peroxisome proliferation and replicative DNA synthesis to the hepatocarcinogenicity of the peroxisome proliferators di(2-ethylhexyl) phthalate and [4-Chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid (Wy-14,643) in rats. Cancer Res 48:6739–6744
Martin PG, Guillou H, Lasserre F, Déjean S, Lan A, Pascussi JM, Sancristobal M, Legrand P, Besse P, Pineau T (2007) Novel aspects of PPARalpha-mediated regulation of lipid and xenobiotic metabolism revealed through a nutrigenomic study. Hepatology 45:767–777
Martinsen TC, Bakke I, Chen D, Sandvik AK, Zahlsen K, Aamo T, Waldum HL (2005) Ciprofibrate stimulates the gastrin-producing cell by acting luminally on antral PPAR-alpha. Am J Physiol Gastrointest Liver Physiol 289:G1052–G1060
Marx N, Sukhova GK, Collins T, Libby P, Plutzky J (1999) PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 99:3125–3131
Masamune A, Shimosegawa T (2009) Signal transduction in pancreatic stellate cells. J Gastroenterol 44:249–260
Masamune A, Kikuta K, Satoh M, Sakai Y, Satoh A, Shimosegawa T (2002) Ligands of peroxisome proliferator-activated receptor-gamma block activation of pancreatic stellate cells. J Biol Chem 277:141–147
Masters C, Crane D (1995) On the role of the peroxisome in ontogeny, aging and degenerative disease. Mech Ageing Dev 80:69–83
Masuda K, Okamoto Y, Tsuura Y, Kato S, Miura T, Tsuda K, Horikoshi H, Ishida H, Seino Y (1995) Effects of troglitazone (CS-045) on insulin secretion in isolated rat pancreatic islets and HIT cells: an insulinotropic mechanism distinct from glibenclamide. Diabetologia 38:24–30
Mathivat A, Cottet J (1953) Clinical trials on the hypocholesterolimia producing effect of 2-phenyl butyric acid. Bull Mem Soc Med Hop Paris 69:1030–1048
Matthiessen MW, Pedersen G, Albrektsen T, Adamsen S, Fleckner J, Brynskov J (2005) Peroxisome proliferator-activated receptor expression and activation in normal human colonic epithelial cells and tubular adenomas. Scand J Gastroenterol 40:198–205
Mattoo V, Eckland D, Widel M (2005) Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study. Clin Ther 27:554–567
Matzkies F, Schulzky D, Berg G (1978) Porcetofen, a new lipid-and urine-acid-reducing substance. Frtschr Med 96:1939–1941
Maurin AC, Chavassieux PM, Meunier PJ (2005) Expression of PPARgamma and beta/delta in human primary osteoblastic cells: influence of polyunsaturated fatty acids. Calcif Tissue Int 76:385–392
McAfee A, Koro C, Landon J, Ziyadeh N, Walker AM (2007) Coronary heart disease outcomes in patients receiving antidiabetic agents. Pharmacoepidemiol Drug Saf 16:711–725
McNew JA, Goodman JM (1994) An oligomeric protein is imported into peroxisomes in vivo. J Cell Biol 127:1245–1257
McNew JA, Goodman JM (1996) The targeting and assembly of peroxisomal proteins: some old rules do not apply. Trends Biochem Sci 21:54–58
Meeker JD, Calafat AM, Hauser R (2009a) Urinary metabolites of di(2-ethylhexyl) phthalate are associated with decreased steroid hormone levels in adult men. J Androl 30:287–297
Meeker JD, Hu H, Cantonwine DE, Lamadrid-Figueroa H, Calafat AM, Ettinger AS, Hernandez-Avila M, Loch-Caruso R, Téllez-Rojo MM (2009b) Urinary phthalate metabolites in relation to preterm birth in Mexico city. Environ Health Persp 117:1587–1592
Meirhaeghe A, Fajas L, Helbecque N, Cottel D, Lebel P, Dallongeville J, Deeb S, Auwerx J, Amouyel P (1998) A genetic polymorphism of the peroxisome proliferator-activated receptor gamma gene influences plasma leptin levels in obese humans. Hum Mol Genet 7:435–440
Meirhaeghe A, Fajas L, Gouilleux F, Cottel D, Helbecque N, Auwerx J, Amouyel P (2003) A functional polymorphism in a STAT5B site of the human PPAR gamma 3 gene promoter affects height and lipid metabolism in a French population. Arterioscler Thromb Vasc Biol 23:289–294
Meissner M, Berlinski B, Doll M, Hrgovic I, Laubach V, Reichenbach G, Kippenberger S, Gille J, Kaufmann R (2011) AP1-dependent repression of TGFα-mediated MMP9 upregulation by PPARδ agonists in keratinocytes. Exp Dermatol 20:425–429
Michalik L, Wahli W (1999) Peroxisome proliferator-activated receptors: three subtypes for a multitude of functions. Curr Opin Biotechnol 10:564–570
Michalik L, Desvergne B, Tan NS, Basu-Modak S, Escher P, Rieusset J, Peters JM, Kaya G, Gonzalez FJ, Zakany J, Metzger D, Chambon P, Duboule DW (2001) Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR)alpha and PPARbeta mutant mice. J Cell Biol 154:799–814
Michiels JF, Perrin C, Leccia N, Massi D, Grimaldi P, Wagner N (2010) PPARbeta activation inhibits melanoma cell proliferation involving repression of the Wilms’ tumour suppressor WT1. Pflugers Arch 459:689–703
Milam JE, Keshamouni VG, Phan SH, Hu B, Gangireddy SR, Hogaboam CM, Standiford TJ, Thannickal VJ, Reddy RC (2007) PPAR-gamma agonists inhibit profibrotic phenotypes in human lung fibroblasts and bleomycin-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 294:L891–L901
Milestone AN, Iacucci M, Ghosh S (2008) Is rosiglitazone a promising treatment for ulcerative colitis? Nat Clin Pract Gastroenterol Hepatol 5:486–487
Minutoli L, Antonuccio P, Polito F, Bitto A, Squadrito F, Irrera N, Nicotina PA, Fazzari C, Montalto AS, Di Stefano V, Romeo C, Altavilla D (2009) Peroxisome proliferator activated receptor beta/delta activation prevents extracellular regulated kinase 1/2 phosphorylation and protects the testis from ischemia and reperfusion injury. J Urol 181:1913–1921
Miyahara T, Schrum L, Rippe R, Xiong S, Yee HF Jr, Motomura K, Anania FA, Willson TM, Tsukamoto H (2000) Peroxisome proliferator-activated receptors and hepatic stellate cell activation. J Biol Chem 275:35715–35722
Miyazaki Y, Mahankali A, Matsuda M, Mahankali S, Hardies J, Cusi K, Mandarino LJ, DeFronzo RA (2002) Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 87:2784–2791
Moffit J, Aleksunes L, Maher J, Scheffer G, Klaassen C, Manautou J (2006) Induction of hepatic transporters multidrug resistance-associated proteins (Mrp) 3 and 4 by clofibrate is regulated by peroxisome proliferator-activated receptor alpha. J Pharmacol Exp Ther 317:537–545
Mohamed MB, Mtiraoui N, Ezzidi I, Chaieb M, Mahjoub T, Almawi WY (2007) Association of the peroxisome proliferator-activated receptor-gamma2 Pro12Ala but not the C1431T gene variants with lower body mass index in type 2 diabetes. J Endocrinol Invest 30:937–943
Monajemi H, Zhang L, Li G, Jeninga EH, Cao H, Maas M, Brouwer CB, Kalkhoven E, Stroes E, Hegele RA, Leff T (2007) Familial partial lipodystrophy phenotype resulting from a single-base mutation in deoxyribonucleic acid-binding domain of peroxisome proliferator-activated receptor-gamma. J Clin Endocrinol Metab 92:1606–1612
Morgan E (1997) Regulation of cytochrome P450 during inflammation and infection. Drug Metab Rev 29:1129–1188
Morimura K, Cheung C, Ward JM, Reddy JK, Gonzalez FJ (2006) Differential susceptibility of mice humanized for peroxisome proliferator-activated receptor alpha to Wy-14,643-induced liver tumorigenesis. Carcinogenesis 27:1074–1080
Morini E, Tassi V, Capponi D, Ludovico O, Dallapiccola B, Trischitta V, Prudente S (2008) Interaction between PPARgamma2 variants and gender on the modulation of body weight. Obesity 16:1467–1470
Morrison A, Yan X, Tong C, Li J (2011) Acute rosiglitazone treatment is cardioprotective against ischemia/reperfusion injury by modulating AMPK, Akt, and JNK signaling in non-diabetic mice. Am J Physiol Heart Circ Physiol 301:H895–H902
Mössner R, Schulz U, Krüger U, Middel P, Schinner S, Füzesi L, Neumann C, Reich K (2002) Agonists of peroxisome proliferator-activated receptor gamma inhibit cell growth in malignant melanoma. J Invest Dermatol 119:576–582
Motojima K, Passilly P, Peters JM, Gonzalez FJ, Latruffe N (1998) Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor alpha and gamma activators in a tissue- and inducer-specific manner. J Biol Chem 273:16710–16714
Motomura W, Okumura T, Takahashi N, Obara T, Kohgo Y (2000) Activation of peroxisome proliferator-activated receptor gamma by troglitazone inhibits cell growth through the increase of p27KiP1 in human pancreatic carcinoma cells. Cancer Res 60:5558–5564
Motomura W, Nagamine M, Tanno S, Sawamukai M, Takahashi N, Kohgo Y, Okumura T (2004) Inhibition of cell invasion and morphological change by troglitazone in human pancreatic cancer cells. J Gastroenterol 39:461–468
Mueller E, Drori S, Aiyer A, Yie J, Sarraf P, Chen H, Hauser S, Rosen ED, Ge K, Roeder RG, Spiegelman BM (2002) Genetic analysis of adipogenesis through peroxisome proliferator-activated receptor gamma isoforms. J Biol Chem 277:41925–41930
Mueller C, Weaver V, Vanden Heuvel JP, August A, Cantorna MT (2003) Peroxisome proliferator-activated receptor gamma ligands attenuate immunological symptoms of experimental allergic asthma. Arch Biochem Biophys 418:186–196
Mukaiyama H, Baba M, Osumi M, Aoyagi S, Kato N, Ohsumi Y, Sakai Y (2004) Modification of a ubiquitin-like protein Paz2 conducted micropexophagy through formation of a novel membrane structure. Mol Biol Cell 15:58–70
Mukherjee R, Jow L, Noonan D, McDonnell DP (1994) Human and rat peroxisome proliferator activated receptors (PPARs) demonstrate similar tissue distribution but different responsiveness to PPAR activators. J Steroid Biochem Mol Biol 51:157–166
Muller D, Theuer J, Shagdarsuren E, Kaergel E, Honeck H, Park J, Markovic M, Barbosa-Sicard E, Dechend R, Wellner M, Kirsch T, Fiebeler A, Rothe M, Haller H, Luft FC, Schunck WH (2004) A peroxisome proliferator-activated receptor-alpha activator induces renal CYP2C23 activity and protects from angiotensin II-induced renal injury. Am J Pathol 164:521–532
Muller-Brusselbach S, Ebrahimsade S, Jäkel J, Eckhardt J, Rapp UR, Peters JM, Moll R, Müller R (2007) Growth of transgenic RAF-induced lung adenomas is increased in mice with a disrupted PPARbeta/delta gene. Int J Oncol 31:607–611
Mylchreest E, Cattley RC, Foster PM (1998) Male reproductive tract malformations in rats following gestational and lactational exposure to Di(n-butyl) phthalate: an antiandrogenic mechanism? Toxicol Sci 43:47–60
Myloma E, Giannopoulou I, Diamantopoulou K, Bakarakos P, Nomikos A, Zervas A, Nakopoulou L (2009) Peroxisome proliferator-activated receptor gamma expression in urothelial carcinomas of the bladder: association with differentiation, proliferation and clinical outcome. Eur J Surg Oncol 35:197–201
Nadra K, Anghel SI, Joye E, Tan NS, Basu-Modak S, Trono D, Wahli W, Desvergne B (2006) Differentiation of trophoblast giant cells and their metabolic functions are dependent on peroxisome proliferator-activated receptor beta/delta. Mol Cell Biol 26:3266–3281
Nagasawa T, Inada Y, Nakano S, Tamura T, Takahashi T, Maruyama K, Yamazaki Y, Kuroda J, Shibata N (2006) Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet. Eur J Pharmacol 536:182–191
Nagata K, Yamazoe Y (2000) Pharmacogenetics of sulfotransferase. Annu Rev Pharmacol Toxicol 40:159–176. doi:10.1146/annurev.pharmtox.40.1.159
Nagy L, Schwabe JW (2004) Mechanism of the nuclear receptor molecular switch. Trends Biochem Sci 29:317–324
Naito H, Yamanoshita O, Kamijima M, Katoh T, Matsunaga T, Lee CH, Kim H, Aoyama T, Gonzalez FJ, Nakajima T (2008) Association of V227A PPARalpha polymorphism with altered serum biochemistry and alcohol drinking in Japanese men. Pharmacogenet Genomics 16:569–577
Nakajima T, Kamijo Y, Tanaka N, Sugiyama E, Tanaka E, Kiyosawa K, Fukushima Y, Peters JM, Gonzalez FJ, Aoyama T (2004) Peroxisome proliferator-activated receptor alpha protects against alcohol-induced liver damage. Hepatology 40:972–980
Namikoshi T, Tomita N, Satoh M, Haruna Y, Kobayashi S, Komai N, Sasaki T, Kashihara N (2008) Pioglitazone enhances the antihypertensive and renoprotective effects of candesartan in Zucker obese rats fed a high-protein diet. Hypertens Res 31:745–755
Nan YM, Fu N, Wu WJ, Liang BL, Wang RQ, Zhao SX, Zhao JM, Yu J (2009) Rosiglitazone prevents nutritional fibrosis and steatohepatitis in mice. Scand J Gastroenterol 44:358–365
Nanji AA, Dannenberg AJ, Jokelainen K, Bass NM (2004) Alcoholic liver injury in the rat is associated with reduced expression of peroxisome proliferator-alpha (PPARalpha)-regulated genes and is ameliorated by PPARalpha activation. J Pharmacol Exp Ther 310:417–424
Narala VR, Adapala RK, Suresh MV, Brock TG, Peters-Golden M, Reddy RC (2010) Leukotriene B4 is a physiologically relevant endogenous peroxisome proliferator-activated receptor-alpha agonist. J Biol Chem 285:22067–22074
Narkar VA, Downes M, Yu RT, Embler E, Wang YX, Banayo E, Mihaylova MM, Nelson MC, Zou Y, Juguilon H, Kang H, Shaw RJ, Evans RM (2008) AMPK and PPARdelta agonists are exercise mimetics. Cell 134:405–415
Necela BM, Su W, Thompson EA (2008) Peroxisome proliferator-activated receptor gamma down-regulates follistatin in intestinal epithelial cells through SP1. J Biol Chem 283:29784–29794
Nelson D, Koymans L, Kamataki T, Stegeman J, Feyereisen R, Waxman D, Waterman M, Gotoh O, Coon M, Estabrook R, Gunsalus I, Nebert D (1996) P450 superfamily: update on new sequences, gene mapping, accession numbers, and nomenclature. Pharmacogenetics 6:1–42
Nemenoff R, Meyer AM, Hudish TM, Mozer AB, Snee A, Narumiya S, Stearman RS, Winn RA, Weiser-Evans M, Geraci MW, Keith RL (2008) Prostacyclin prevents murine lung cancer independent of the membrane receptor by activation of peroxisomal proliferator–activated receptor gamma. Cancer Prev Res 1:349–356
Neschen S, Morino K, Dong J, Wang-Fischer Y, Cline GW, Romanelli AJ, Rossbacher JC, Moore IK, Regittnig W, Munoz DS, Kim JH, Shulman GI (2007) n-3 Fatty acids preserve insulin sensitivity in vivo in a peroxisome proliferator-activated receptor-alpha-dependent manner. Diabetes 56:1034–1041
Nesto R, Bell D, Bonow R, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R (2003) Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American heart association and American diabetes association. Circulation 108:2941–2948
Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR (2003) Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 38:1008–1017
Nicol CJ, Yoon M, Ward JM, Yamashita M, Fukamachi K, Peters JM, Gonzalez FJ (2004) PPARgamma influences susceptibility to DMBA-induced mammary, ovarian and skin carcinogenesis. Carcinogenesis 25:1747–1755
Nicolakakis N, Aboulkassim T, Ongali B, Lecrux C, Fernandes P, Rosa-Neto P, Tong XK, Hamel E (2008) Complete rescue of cerebrovascular function in aged Alzheimer’s disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor gamma agonist. J Neurosci 28:9287–9296
Nielsen R, Grontved L, Stunnenberg HG, Mandrup S (2006) Peroxisome proliferator-activated receptor subtype-and cell-type-specific activation of genomic target genes upon adenoviral transgene delivery. Mol Cell Biol 26:5698–5714
Nilsson E, Poulsen P, Sjögren M, Ling C, Ridderstråle M, Groop L, Vaag A (2007) Regulation of skeletal muscle PPAR delta mRNA expression in twins. J Physiol 584:1011–1017
Nisbet RE, Sutliff RL, Hart CM (2007) The role of peroxisome proliferator-activated receptors in pulmonary vascular disease. PPAR Res 2007:18797
Nissen S, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356:2457–2471
Nissen S, Wolski K (2010) Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 170:1191–1201
Nissen SE, Wolski K, Topol EJ (2005) Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 294:2581–2586
Nolte RT, Wisely GB, Westin S, Cobb JE, Lambert MH, Kurokawa R, Rosenfeld MG, Willson TM, Glass CK, Milburn MV (1998) Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature 395:137–143
Norris JD, Joseph JD, Sherk AB, Juzumiene D, Turnbull PS, Rafferty SW, Cui H, Anderson E, Fan D, Dye DA, Deng X, Kazmin D, Chang C-Y, Wilson TM, McDonnell DP (2009) Differential presentation of protein interaction surfaces on the androgen receptor defines the pharmacological actions of bound ligands. Chem Biol 16:452–460
Oakes ND, Kennedy CJ, Jenkins AB, Laybutt DR, Chisholm DJ, Kraegen EW (1994) A new antidiabetic agent, BRL-49653, reduces lipid availability and improves insulin action and glucoregulation in the rat. Diabetes 43:1203–1210
Oberkofler H, Esterbauer H, Linnemayr V, Strosberg AD, Krempler F, Patsch W (2002) Peroxisome proliferator activated receptor (PPAR) γ coactivator-1 recruitment regulates PPAR subtype specificity. J Biol Chem 277:16750–16757
Obih P, Oyekan AO (2008) Regulation of blood pressure, natriuresis and renal thiazide/amiloride sensitivity in PPARalpha null mice. Blood Press 17:55–63
Odegaard JI, Ricardo-Gonzalez RR, Goforth MH, Morel CR, Subramanian V, Mukundan L, Red Eagle A, Vats D, Brombacher F, Ferrante AW, Chawla A (2007) Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature 447:1116–1120
Odegaard JI, Ricardo-Gonzalez RR, Red Eagle A, Vats D, Morel CR, Goforth MH, Subramanian V, Mukundan L, Ferrante AW, Chawla A (2008) Alternative M2 activation of Kupffer cells by PPARdelta ameliorates obesity-induced insulin resistance. Cell Metab 7:496–507
Ogata M, Tsujita M, Hossain MA, Akita N, Gonzalez FJ, Staels B, Suzuki S, Fukutomi T, Kimura G, Yokoyama S (2009) On the mechanism for PPAR agonists to enhance ABCA1 gene expression. Atherosclerosis 205:413–419
Ogino S, Shima K, Baba Y, Nosho K, Irahara N, Kure S, Chen L, Toyoda S, Kirkner GJ, Wang YL, Giovannucci EL, Fuchs CS (2009) Colorectal cancer expression of peroxisome proliferator-activated receptor gamma (PPARG, PPARgamma) is associated with good prognosis. Gastroenterology 136:1242–1250
Oh SH, Park SM, Lee YH, Cha JY, Lee JY, Shin EK, Park JS, Park BL, Shin HD, Park CS (2009) Association of peroxisome proliferator-activated receptor-gamma gene polymorphisms with the development of asthma. Respir Med 103:1020–1024
Ohga S, Shikata K, Yozai K, Okada S, Ogawa D, Usui H, Wada J, Shikata Y, Makino H (2007) Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-kappaB activation. Am J Physiol Renal Physiol 292:F1141–F1150
Oishi K, Koyanagi S, Matsunaga N, Kadota K, Ikeda E, Hayashida S, Kuramoto Y, Shimeno H, Soeda S, Ohdo S (2010) Bezafibrate induces plasminogen activator inhibitor-1 gene expression in a clock-dependent circadian manner. Mol Pharmacol 78:135–141
Oleksiewicz MB, Thorup I, Nielsen HS, Andersen HV, Hegelund AC, Iversen L, Guldberg TS, Brinck PR, Sjogren I, Thinggaard UK, Jørgensen L, Jensen MB (2005) Generalized cellular hypertrophy is induced by a dual-acting PPAR agonist in rat urinary bladder urothelium in vivo. Toxicol Pathol 33:552–560
Oleksiewicz MB, Southgate J, Iversen L, Egerod FL (2008) Rat urinary bladder carcinogenesis by dual-acting PPARalpha + gamma Agonists. PPAR Res 2008:103167
Ollero M, Junaidi O, Zaman MM, Tzameli I, Ferrando AA, Andersson C, Blanco PG, Bialecki E, Freedman SD (2004) Decreased expression of peroxisome proliferator activated receptor gamma in cftr−/− mice. J Cell Physiol 200:235–244
Osabe M, Sugatani J, Fukuyama T, Ikushiro S, Ikari A, Miwa M (2008) Expression of hepatic UDP-glucuronosyltransferase 1A1 and 1A6 correlated with increased expression of the nuclear constitutive androstane receptor and peroxisome proliferator-activated receptor alpha in male rats fed a high-fat and high-sucrose diet. Drug Metab Dispos 36:294–302
O’Sullivan SE, Kendall DA (2010) Cannabinoid activation of peroxisome proliferator-activated receptors: potential for modulation of inflammatory disease. Immunobiology 215:611–616
Oude Elferink R, Jansen P (1994) The role of the canalicular multispecific organic anion transporter in the disposal of endo- and xenobiotics. Pharmacol Ther 64:77–97
Owens S, Basu N, Banerjee R (2005) UDP-glucuronosyltransferases: gene structures of UGT1 and UGT2 families. Methods Enzymol 400:1–22. doi:10.1016/S0076-6879(05)00001-7
Palmer CN, Hsu MH, Griffin KJ, Raucy JL, Johnson EF (1998) Peroxisome proliferator activated receptor-alpha expression in human liver. Mol Pharmacol 53:14–22
Palmer CN, Doney AS, Ismail T, Lee SP, Murrie I, Macgregor DF, Mukhopadhyay S (2007) PPARG locus haplotype variation and exacerbations in asthma. Clin Pharmacol Ther 81:713–718
Pan G, Hanaoka T, Yoshimura M, Zhang S, Wang P, Tsukino H, Inoue K, Nakazawa H, Tsugane S, Takahashi K (2006) Decreased serum free testosterone in workers exposed to high levels of di-n-butyl phthalate (DBP) and di-2-ethylhexyl phthalate (DEHP): a cross-sectional study in China. Environ Health Persp 114:1643–1648
Pang M, de la Monte SM, Longato L, Tong M, He J, Chaudhry R, Duan K, Ouh J, Wands JR (2009) PPARdelta agonist attenuates alcohol-induced hepatic insulin resistance and improves liver injury and repair. J Hepatol 50:1192–11201
Panigrahy D, Kaipainen A, Kieran MW, Huang S (2008) PPARs: a double-edged sword in cancer therapy? PPAR Res 2008:350351
Park CW, Kim HW, Ko SH, Chung HW, Lim SW, Yang CW, Chang YS, Sugawara A, Guan Y, Breyer MD (2006) Accelerated diabetic nephropathy in mice lacking the peroxisome proliferator-activated receptor alpha. Diabetes 55:885–893
Park JK, Ki MR, Lee HR, Hong IH, Ji AR, Ishigami A, Park SI, Kim JM, Chung HY, Yoo SE, Jeong KS (2010) Vitamin C deficiency attenuates liver fibrosis by way of up-regulated peroxisome proliferator-activated receptor-gamma expression in senescence marker protein 30 knockout mice. Hepatology 51:1766–1777
Patel HJ, Belvisi MG, Bishop-Bailey D, Yacoub MH, Mitchell JA (2003) Activation of peroxisome proliferator-activated receptors in human airway smooth muscle cells has a superior anti-inflammatory profile to corticosteroids: relevance for chronic obstructive pulmonary disease therapy. J Immunol 170:2663–2669
Patel NS, di Paola R, Mazzon E, Britti D, Thiemermann C, Cuzzocrea S (2009) Peroxisome proliferator-activated receptor-alpha contributes to the resolution of inflammation after renal ischemia/reperfusion injury. J Pharmacol Exp Ther 328:635–643
Pathak R, Asad M, Hrishikeshavan HJ, Prasad S (2007) Effect of peroxisome proliferator-activated receptor-alpha agonist (bezafibrate) on gastric secretion and gastric cytoprotection in rats. Fundam Clin Pharmacol 21:291–296
Pedchenko TV, Gonzalez AL, Wang D, DuBois RN, Massion PP (2008) Peroxisome proliferator-activated receptor beta/delta expression and activation in lung cancer. Am J Respir Cell Mol Biol 39:689–696
Perez A, van Heeckeren AM, Nichols D, Gupta S, Eastman JF, Davis PB (2008) Peroxisome proliferator-activated receptor-gamma in cystic fibrosis lung epithelium. Am J Physiol Lung Cell Mol Physiol 295:L303–L313
Peters JM, Cattley RC, Gonzalez FG (1997) Role of PPAR alpha in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy-14,643. Carcinogenesis 18:2029–2033
Peters JM, Lee SST, Li W, Ward JM, Gavrilova O, Everett C, Reitman ML, Hudson LD, Gonzalez FJ (2000a) Growth, adipose, brain and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor β(δ). Mol Cell Biol 20:5119–5128
Peters J, Rusyn I, Rose M, Gonzalez F, Thurman RG (2000b) Peroxisome proliferator-activated receptor α is restricted to hepatic parenchymal cells, not kupffer cells: implications for the mechanism of action of peroxisome proliferators in hepatocarcinogenesis. Carcinogenesis 21:823–826
Peters JM, Hollingshead HE, Gonzalez FJ (2008) Role of peroxisome-proliferator-activated receptor beta/delta (PPARbeta/delta) in gastrointestinal tract function and disease. Clin Sci (Lond) 115:107–127
Peyrin-Biroulet L, Beisner J, Wang G, Nuding S, Oommen ST, Kelly D, Parmentier-Decrucq E, Dessein R, Merour E, Chavatte P, Grandjean T, Bressenot A, Desreumaux P, Colombel JF, Desvergne B, Stange EF, Wehkamp J, Chamaillard M (2010) Peroxisome proliferator-activated receptor gamma activation is required for maintenance of innate antimicrobial immunity in the colon. Proc Natl Acad Sci USA 107:8772–8777
Phadke SR, Gupta N, Girisha KM, Kabra M, Maeda M, Vidal E, Moser A, Steinberg S, Puri RD, Verma IC, Braverman N (2010) Rhizomelic chondrodysplasia punctata type 1: report of mutations in 3 children from India. J Appl Genet 51:107–110
Pineda Torra I, Jamshidi Y, Flavell DM, Fruchart JC, Staels B (2002) Characterization of the human PPARalpha promoter: identification of a functional nuclear receptor response element. Mol Endocrinol 16:1013–1028
Poll-The BT, Gärtner J (2012) Clinical diagnosis, biochemical findings and MRI spectrum of peroxisomal disorders. Biochim Biophys Acta 1822:1421–1429
Portilla D (2003) Energy metabolism and cytotoxicity. Semin Nephrol 23:432–438
Powell EE, Waters MJ, Jonsson JR (2009) Kupffer cells and hepatocyte metabolism: a two-way street? Hepatology 49:690–692
Prasad KN, Saxena A, Ghoshal UC, Bhagat MR, Krishnani N (2008) Analysis of Pro12Ala PPAR gamma polymorphism and Helicobacter pylori infection in gastric adenocarcinoma and peptic ulcer disease. Ann Oncol 19:1299–1303
Promrat K, Lutchman G, Uwaifo GI, Freedman RJ, Soza A, Heller T, Doo E, Ghany M, Premkumar A, Park Y, Liang TJ, Yanovski JA, Kleiner DE, Hoofnagle JH (2004) A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 39:188–196
Puigserver P, Wu Z, Park CW, Graves R, Wright M, Spiegelman BM (1998) A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 92:829–839
Qin X, Xie X, Fan Y, Tian J, Guan Y, Wang X, Zhu Y, Wang N (2008) Peroxisome proliferator-activated receptor-delta induces insulin-induced gene-1 and suppresses hepatic lipogenesis in obese diabetic mice. Hepatology 48:432–441
Rakhshandehroo M, Sanderson LM, Matilainen M, Stienstra R, Carlberg C, de Groot PJ, Müller M, Kersten S (2007) Comprehensive analysis of PPARalpha-dependent regulation of hepatic lipid metabolism by expression profiling. PPAR Res 2007:26839
Ramanan S, Kooshki M, Zhao W, Hsu FC, Robbins ME (2008) PPARalpha ligands inhibit radiation-induced microglial inflammatory responses by negatively regulating NF-kappaB and AP-1 pathways. Free Radic Biol Med 45:1695–1704
Rashid-Kolvear F, Taboski MA, Nguyen J, Wang DY, Harrington LA, Done SJ (2010) Troglitazone suppresses telomerase activity independently of PPAR gamma in estrogen-receptor negative breast cancer cells. BMC Cancer 10:390
Ratner RE, Parikh S, Tou C (2007) Efficacy, safety and tolerability of tesaglitazar when added to the therapeutic regimen of poorly controlled insulin-treated patients with type 2 diabetes. Diab Vasc Dis Res 4:214–221
Reddy JK, Krishnakantha TP (1975) Hepatic peroxisome proliferation: induction by two novel compounds structurally unrelated to clofibrate. Science 190:787–789
Reddy JK, Azamoff DL, Hignite CE (1980) Hypolipidaemic hepatic peroxisome proliferators form a novel class of chemical carcinogens. Nature 283:397–398
Reddy RC, Srirangam A, Reddy K, Chen J, Gangireddy S, Kalemkerian GP, Standiford TJ, Keshamouni VG (2008) Chemotherapeutic drugs induce PPAR-gamma expression and show sequence-specific synergy with PPAR-gamma ligands in inhibition of non-small cell lung cancer. Neoplasia 10:597–603
Rehan VK, Sakurai R, Corral J, Krebs M, Ibe B, Ihida-Stansbury K, Torday JS (2010) Antenatally administered PPAR-gamma agonist rosiglitazone prevents hyperoxia-induced neonatal rat lung injury. Am J Physiol Lung Cell Mol Physiol 299:L672–L680
Ren H, Aleksunes LM, Wood C, Vallanat B, George MH, Klaassen CD, Corton JC (2010) Characterization of peroxisome proliferator-activated receptor alpha–independent effects of PPARalpha activators in the rodent liver: di-(2-ethylhexyl) phthalate also activates the constitutive-activated receptor. Toxicol Sci 113:45–59
Richert L, Price S, Chesne C, Maita K, Carmichael N (1996) Comparison of induction of hepatic peroxisome proliferation by the herbicide oxadiazon in vivo in rats, mice and dogs and in vitro in rat and human hepatocytes. Toxicol Appl Pharmacol 141:35–43
Ringseis R, Lüdi S, Hirche F, Eder K (2008) Treatment with pharmacological peroxisome proliferator-activated receptor alpha agonist clofibrate increases intestinal carnitine absorption in rats. Pharmacol Res 58:58–64
Rivier M, Safonova I, Lebrun P, Griffiths CE, Ailhaud G, Michel S (1998) Differential expression of peroxisome proliferator-activated receptor subtypes during the differentiation of human keratinocytes. J Invest Dermatol 111:1116–1121
Roduit R, Morin J, Massé F, Segall L, Roche E, Newgard CB, Assimacopoulos-Jeannet F, Prentki M (2000) Glucose down-regulates the expression of the peroxisome proliferator-activated receptor-alpha gene in the pancreatic beta -cell. J Biol Chem 275:35799–35806
Rogers NH, Perfield JW 2nd, Strissel KJ, Obin MS, Greenberg AS (2010) Loss of ovarian function in mice results in abrogated skeletal muscle PPARdelta and FoxO1-mediated gene expression. Biochem Biophys Res Commun 392:1–3
Rolfe M, James N, Roberts R (1997) Tumor necrosis factor α (TNF α) suppresses apoptosis and induces DNA synthesis in rodent hepatocytes: a mediator of the hepatocarcinogenicity of peroxisome proliferators? Carcinogenesis 18:2277–2280
Roman J (2008) Peroxisome proliferator-activated receptor gamma and lung cancer biology: implications for therapy. J Invest Med 56:528–533
Roman RJ, Ma YH, Frohlich B, Markham B (1993) Clofibrate prevents the development of hypertension in Dahl salt-sensitive rats. Hypertension 21:985–988
Romanowska M, Reilly L, Palmer CN, Gustafsson MC, Foerster J (2010) Activation of PPARbeta/delta causes a psoriasis-like skin disease in vivo. PLoS One 5:e9701
Rose M, Germolec DR, Schoonhoven R, Thurman RG (1997) Kupffer cells are casually responsible for mitogenic effect of peroxisome proliferators. Carcinogenesis 18:1453–1456
Rosen C (2007) The rosiglitazone story—lessons from an FDA advisory committee meeting. N Engl J Med 357:844–846
Roussel F, Marie S, Cresteil T (1995) Gene structure and promoter analysis of the rat constitutive CYP2C23 gene. DNA Cell Biol 14:777–788
Ruan XZ, Moorhead JF, Fernando R, Wheeler DC, Powis SH, Varghese Z (2003) PPAR agonists protect mesangial cells from interleukin 1beta-induced intracellular lipid accumulation by activating the ABCA1 cholesterol efflux pathway. J Am Soc Nephrol 14:593–600
Ruan X, Zheng F, Guan Y (2008) PPARs and the kidney in metabolic syndrome. Am J Physiol Renal Physiol 294:F1032–F1047
Rubenstrunk A, Hanf R, Hum DW, Fruchart JC, Staels B (2007) Safety issues and prospects for future generations of PPAR modulators. Biochim Biophys Acta 1771:1065–1081
Rubin LJ (1999) Cellular and molecular mechanisms responsible for the pathogenesis of primary pulmonary hypertension. Pediatr Pulmonol Suppl 18:194–197
Rucktäschel R, Halbach A, Girzalsky W, Rottensteiner H, Erdmann R (2010) De novo synthesis of peroxisomes upon mitochondrial targeting of Pex3p. Eur J Cell Biol 89:947–954
Rucktäschel R, Girzalsky W, Erdmann R (2011) Protein import machineries of peroxisomes. Biochim Biophys Acta 1808:892–900
Ruge F, Glavini A, Gallimore AM, Richards HE, Thomas CP, O'Donnell VB, Philpott MP, Porter RM (2011) Delineating immune-mediated mechanisms underlying hair follicle destruction in the mouse mutant defolliculated. J Invest Dermatol 131:572–579
Runge-Morris M, Kocarek T (2009) Regulation of sulfotransferase and UDP-glucuronosyltransferase gene expression by the PPARs. PPAR Res 2009:728941
Russell AP, Feilchenfeldt J, Schreiber S, Praz M, Crettenand A, Gobelet C, Meier CA, Bell DR, Kralli A, Giacobino JP, Dériaz O (2003) Endurance training in humans leads to fiber type-specific increases in levels of peroxisome proliferator-activated receptor-gamma coactivator-1 and peroxisome proliferator-activated receptor-alpha in skeletal muscle. Diabetes 52:2874–2881
Ryu S, Kawabe T, Nada S, Yamaguchi A (2000) Identification of basic residues involved in drug export function of human multidrug resistance-associated protein 2. J Biol Chem 275:39617–39624
Rzonca SO, Suva LJ, Gaddy D, Montague DC, Lecka-Czernik B (2004) Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 145:401–406
Saez E, Saez E, Tontonoz P, Nelson MC, Alvarez JG, Ming UT, Baird SM, Thomazy VA, Evans RM (1998) Activators of the nuclear receptor PPARgamma enhance colon polyp formation. Nat Med 4:1058–1061
Saito K, Kobayashi K, Mizuno Y, Fukuchi Y, Furihata T, Chiba K (2010) Peroxisome proliferator-activated receptor alpha (PPARalpha) agonists induce constitutive androstane receptor (CAR) and cytochrome P450 2B in rat primary hepatocytes. Drug Metab Pharmacokinet 25:108–111
Salvadó L, Serrano-Marco L, Barroso E, Palomer X, Vázquez-Carrera M (2012) Targeting PPARβ/δ for the treatment of type 2 diabetes mellitus. Expert Opin Ther Targets 16:209–223
Sánchez-Hidalgo M, Martín AR, Villegas I, Alarcón De La Lastra C (2005) Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, reduces chronic colonic inflammation in rats. Biochem Pharmacol 69:1733–1744
Sapone A, Peters JM, Sakai S, Tomita S, Papiha SS, Dai R, Friedman FK, Gonzalez FJ (2000) The human peroxisome proliferator-activated receptor alpha gene: identification and functional characterization of two natural allelic variants. Pharmacogenetics 10:321–333
Sarafidis PA, Bakris GL (2006) Protection of the kidney by thiazolidinediones: an assessment from bench to bedside. Kidney Int 70:1223–1233
Sarraf P, Mueller E, Jones D, King FJ, DeAngelo DJ, Partridge JB, Holden SA, Chen LB, Singer S, Fletcher C, Spiegelman BM (1998) Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med 4:1046–1052
Sasaki H, Tanahashi M, Yukiue H, Moiriyama S, Kobayashi Y, Nakashima Y, Kaji M, Kiriyama M, Fukai I, Yamakawa Y, Fujii Y (2002) Decreased peroxisome proliferator-activated receptor gamma gene expression was correlated with poor prognosis in patients with lung cancer. Lung Cancer 36:71–76
Sato H, Ishihara S, Kawashima K, Moriyama N, Suetsugu H, Kazumori H, Okuyama T, Rumi MA, Fukuda R, Nagasue N, Kinoshita Y (2000) Expression of peroxisome proliferator-activated receptor (PPAR)gamma in gastric cancer and inhibitory effects of PPARgamma agonists. Br J Cancer 83:1394–1400
Satoh T, Toyoda M, Hoshino H, Monden T, Yamada M, Shimizu H, Miyamoto K, Mori M (2002) Activation of peroxisome proliferator-activated receptor-gamma stimulates the growth arrest and DNA-damage inducible 153 gene in non-small cell lung carcinoma cells. Oncogene 21:2171–2180
Sayan-Ozacmak H, Ozacmak VH, Barut F, Jakubowska-Dogru E (2011) Neuroprotective efficacy of the peroxisome proliferator-activated receptor-γ ligand in chronic cerebral hypoperfusion. Curr Neurovasc Res 8:190–199
Scatena R, Bottoni P, Giardina B (2008) Mitochondria, PPARs, and cancer: is receptor-independent action of PPAR agonists a key? PPAR Res 2008:256251
Schaefer KL, Wada K, Takahashi H, Matsuhashi N, Ohnishi S, Wolfe MM, Turner JR, Nakajima A, Borkan SC, Saubermann LJ (2005) Peroxisome proliferator-activated receptor gamma inhibition prevents adhesion to the extracellular matrix and induces anoikis in hepatocellular carcinoma cells. Cancer Res 65:2251–2259
Schaefer MB, Pose A, Ott J, Hecker M, Behnk A, Schulz R, Weissmann N, Günther A, Seeger W, Mayer K (2008) Peroxisome proliferator-activated receptor-alpha reduces inflammation and vascular leakage in a murine model of acute lung injury. Eur Respir J 32:1344–1353
Schernthaner G, Chilton RJ (2010) Cardiovascular risk and thiazolidinediones–what do meta-analyses really tell us? Diabetes Obes Metab 12:1023–1035
Schernthaner G, Matthews D, Charbonnel B, Hanefeld M, Brunetti P (2004) Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metab 89:6068–6076
Schmidt A, Endo N, Rutledge SJ, Vogel R, Shinar D, Rodan GA (1992) Identification of a new member of the steroid hormone receptor superfamily that is activated by a peroxisome proliferator and fatty acids. Mol Endocrinol 6:1634–1641
Schmuth M, Schoonjans K, Yu QC, Fluhr JW, Crumrine D, Hachem JP, Lau P, Auwerx J, Elias PM, Feingold KR (2002) Role of peroxisome proliferator-activated receptor alpha in epidermal development in utero. J Invest Dermatol 119:1298–1303
Schopfer FJ, Lin Y, Baker PR, Cui T, Garcia-Barrio M, Zhang J, Chen K, Chen YE, Freeman BA (2005) Nitrolinoleic acid: an endogenous peroxisome proliferator-activated receptor gamma ligand. Proc Natl Acad Sci USA 102:2340–2345
Schopfer FJ, Cole MP, Groeger AL, Chen CS, Khoo NK, Woodcock SR, Golin-Bisello F, Motanya UN, Li Y, Zhang J, Garcia-Barrio MT, Rudolph TK, Rudolph V, Bonacci G, Baker PR, Xu HE, Batthyany CI, Chen YE, Hallis TM, Freeman BA (2010) Covalent peroxisome proliferator-activated receptor gamma adduction by nitro-fatty acids: selective ligand activity and anti-diabetic signaling actions. J Biol Chem 285:12321–12333
Schrader M, Fahimi HD (2008) The peroxisome: still a mysterious organelle. Histochem Cell Biol 129:421–440
Schupp M, Lazar MA (2010) Endogenous ligands for nuclear receptors: digging deeper. J Biol Chem 285:40409–40415
Schwartz AV (2008) TZDs and bone a review of the recent clinical evidence. PPAR Res 2008:297893
Sen U, Rodriguez WE, Tyagi N, Kumar M, Kundu S, Tyagi SC (2008) Ciglitazone, a PPARgamma agonist, ameliorates diabetic nephropathy in part through homocysteine clearance. Am J Physiol Endocrinol Metab 295:E1205–E1212
Senekeo-Effenberger K, Chen S, Brace-Sinnokrak E, Bonzo JA, Yueh MF, Argikar U, Kaeding J, Trottier J, Remmel RP, Ritter JK, Barbier O, Tukey RH (2007) Expression of the human UGT1 locus in transgenic mice by 4-chloro-6-(2,3-xylidino)-2-pyrimidinylthioacetic acid (WY-14643) and implications on drug metabolism through peroxisome proliferator-activated receptor α activation. Drug Metab Dispos 35:419–427. doi:10.1124/dmd.106.013243
Sertznig P, Seifert M, Tilgen W, Reichrath J (2008) Peroxisome proliferator-activated receptors (PPARs) and the human skin: importance of PPARs in skin physiology and dermatologic diseases. Am J Clin Dermatol 9:15–31
Shan W, Nicol CJ, Ito S, Bility MT, Kennett MJ, Ward JM, Gonzalez FJ, Peters JM (2008a) Peroxisome proliferator-activated receptor-beta/delta protects against chemically induced liver toxicity in mice. Hepatology 47:225–235
Shan W, Palkar P, Murray I, McDevitt E, Kennett M, Kang B, Isom H, Perdew G, Gonzalez FJ, Peters JM (2008b) Ligand activation of peroxisome proliferator-activated receptor-beta/delta attenuates carbon tetrachloride hepatotoxicity by downregulating proinflammatory genes. Toxicol Sci 105:418–428
Shaw N, Elholm M, Noy N (2003) Retinoic acid is a high affinity selective ligand for the peroxisome proliferator-activated receptor beta/delta. J Biol Chem 278:41589–41592
Sher T, Yi HF, McBride OW, Gonzalez FJ (1993) cDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor. Biochemistry 32:5598–5604
Sheu MY, Fowler AJ, Kao J, Schmuth M, Schoonjans K, Auwerx J, Fluhr JW, Man MQ, Elias PM, Feingold KR (2002) Topical peroxisome proliferator activated receptor-alpha activators reduce inflammation in irritant and allergic contact dermatitis models. J Invest Dermatol 118:94–101
Shimada T, Fujii Y, Koike T, Tabei K, Namatame T, Yamagata M, Tajima A, Yoneda M, Terano A, Hiraishi H (2006) Peroxisome proliferator-activated receptor gamma (PPARgamma) regulates trefoil factor family 2 (TFF2) expression in gastric epithelial cells. Int J Biochem Cell Biol 39:626–637
Shimomura K, Ikeda M, Ariyama Y, Proks P, Shimomura Y, Mori M, Matsumoto S (2006) Effect of peroxisome proliferator-activated receptor alpha ligand fenofibrate on K(v) channels in the insulin-secreting cell line HIT-T15. Gen Physiol Biophys 25:455–460
Silswal N, Parelkar NK, Wacker MJ, Badr M, Andresen J (2012) PPARα-independent arterial smooth muscle relaxant effects of PPARα agonists. PPAR Res 2012:302495
Sime PJ (2008) The antifibrogenic potential of PPARgamma ligands in pulmonary fibrosis. J Investig Med 56:534–538
Simó R, Rodriguez A, Caveda E (2010) Different effects of thiazolidinediones on cardiovascular risk in patients with type 2 diabetes mellitus: pioglitazone versus rosiglitazone. Curr Drug Saf 5:234–244
Simon DM, Arikan MC, Srisuma S, Bhattacharya S, Andalcio T, Shapiro SD, Mariani TJ (2006) Epithelial cell PPARgamma is an endogenous regulator of normal lung maturation and maintenance. Proc Am Thoracic Soc 3:510–511
Singh S, Loke Y, Furberg C (2007) Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 298:1189–1195
Skogsberg J, Kannisto K, Roshani L, Gagne E, Hamsten A, Larsson C, Ehrenborg E (2000) Characterization of the human peroxisome proliferator activated receptor delta gene and its expression. Int J Mol Med 6:73–81
Skogsberg J, Kannisto K, Cassel TN, Hamsten A, Eriksson P, Ehrenborg E (2003a) Evidence that peroxisome proliferator-activated receptor delta influences cholesterol metabolism in men. Arterioscler Thromb Vasc Biol 23:637–643
Skogsberg J, McMahon AD, Karpe F, Hamsten A, Packard CJ, Ehrenborg E (2003b) Peroxisome proliferator activated receptor delta genotype in relation to cardiovascular risk factors and risk of coronary heart disease in hypercholesterolaemic men. J Intern Med 254:597–604
Smeets PJ, Teunissen BE, Planavila A, de Vogel-van den Bosch H, Willemsen PH, van der Vusse GJ, van Bilsen M (2008) Inflammatory pathways are activated during cardiomyocyte hypertrophy and attenuated by peroxisome proliferator-activated receptors PPARalpha and PPARdelta. J Biol Chem 283:29109–29118
Smith S, De Jonge L, Volaufova J (2005) Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial. Metabolism 54:24–32
Smulders YM, van Eeden AE, Stehouwer CD, Weijers RN, Slaats EH, Silberbusch J (1997) Can reduction in hypertriglyceridaemia slow progression of microalbuminuria in patients with non-insulin-dependent diabetes mellitus? Eur J Clin Invest 27:997–1002
Sohda T, Mizuno K, Tawada H, Sugiyama Y, Fujita T, Kawamatsu Y (1982a) Studies on antidiabetic agents I: synthesis of 5-[4-(2-methyl-2-phenylpropoxy)-benzyl]thiazolidine-2,4-dione (AL-321) and related compounds. Chem Pharm Bull(Tokyo) 30:3563–3573
Sohda T, Mizuno K, Imamiya A, Sugiyama Y, Fujita T, Kawamatsu Y (1982b) Studies on antidiabetic agents II: synthesis of 5-[4-(1-methylcyclohexyl methoxy)-benzyl]thiazolidine-2,4-dione (ADD-3878) and its derivatives. Chem Pharm Bull(Tokyo) 30:3580–3600
Sohda T, Momose Y, Meguro K, Kawamatsu Y, Sugiyama Y, Ikeda H (1990) Studies on antidiabetic agents. Synthesis and hypoglycemic activity of 5-[4-(pyridylalkoxy) benzyl]-2,4-thiazolidinediones. Arzneimitteleforschung 40:37–42
Solbach T, Paulus B, Weyand M, Eschenhagen T, Zolk O, Fromm M (2008) Naunyn Schmiedebergs ATP-binding cassette transporters in human heart failure. Arch Pharmacol 377:231–243
Sonoda J, Pei L, Evans R (2008) Nuclear receptors: decoding metabolic disease. FEBS Lett 582:2–9
Sottile V, Seuwen K, Kneissel M (2004) Enhanced marrow adipogenesis and bone resorption in estrogen-deprived rats treated with the PPARgamma agonist BRL49653 (rosiglitazone). Calcif Tissue Int 75:329–337
Souza LL, Cordeiro A, Oliveira LS, Paula GS, Faustino LC, Ortiga-Carvalho TM, Oliveira KJ, Pazos-Moura CC (2011) Thyroid hormone contributes to the hypolipidemic effect of polyunsaturated fatty acids from fish oil: in vivo evidence for cross talking mechanisms. J Endocrinol 211:65–72
Spears M, McSharry C, Thomson NC (2006) Peroxisome proliferator-activated receptor-gamma agonists as potential anti-inflammatory agents in asthma and chronic obstructive pulmonary disease. Clin Exp Allergy 36:1494–1504
Spiegelman B (1998) PPARγ in monocytes: less pain, any gain. Cell 93:153–155
Spiegelman B, Flier J (1996) Adipogenesis and obesity: rounding out the big picture. Cell 87:377–389
Staels B, Koenig W, Habib A, Merval R, Lebret M, Torra IP, Delerive P, Fadel A, Chinetti G, Fruchart JC, Najib J, Maclouf J, Tedgui A (1998) Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature 393:790–793
Staumont-Sallé D, Abboud G, Brénuchon C, Kanda A, Roumier T, Lavogiez C, Fleury S, Rémy P, Papin JP, Bertrand-Michel J, Tercé F, Staels B, Delaporte E, Capron M, Dombrowicz D (2008) Peroxisome proliferator-activated receptor alpha regulates skin inflammation and humoral response in atopic dermatitis. J Allergy Clin Immunol 121:962–968
Steinberg SJ, Dodt G, Raymond GV, Braverman NE, Moser AB, Moser HW (2006) Peroxisome biogenesis disorders. Biochim Biophys Acta 1763:1733–1748
Still K, Grabowski P, Mackie I, Perry M, Bishop N (2008) The peroxisome proliferator activator receptor alpha/delta agonists linoleic acid and bezafibrate upregulate osteoblast differentiation and induce periosteal bone formation in vivo. Calcif Tissue Int 83:285–292
Su CG, Wen X, Bailey ST, Jiang W, Rangwala SM, Keilbaugh SA, Flanigan A, Murthy S, Lazar MA, Wu GD (1999) A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. J Clin Invest 104:383–389
Su W, Bush CR, Necela BM, Calcagno SR, Murray NR, Fields AP, Thompson EA (2007) Differential expression, distribution, and function of PPAR-gamma in the proximal and distal colon. Physiol Genomics 30:342–353
Suk FM, Chen CH, Lin SY, Cheng CJ, Yen SJ, Hung LF, Liu DZ, Liang YC (2009) 15-deoxy-Delta(12,14)-prostaglandin J(2) inhibits fibrogenic response in human hepatoma cells. Toxicol Lett 187:22–27
Sumanasekera WK, Tien ES, Davis JW 2nd, Turpey R, Perdew GH, Vanden Heuvel JP (2003) Heat shock protein-90 (Hsp90) acts as a repressor of peroxisome proliferator-activated receptor-alpha (PPARalpha) and PPARbeta activity. Biochemistry 42:10726–10735
Sun Y, Alexander SP, Kendall DA, Bennett AJ (2006) Cannabinoids and PPARalpha signaling. Biochem Soc Trans 34:1095–1097
Sun Y, Alexander SP, Garle MJ, Gibson CL, Hewitt K, Murphy SP, Kendall DA, Bennett AJ (2007) Cannabinoid activation of PPAR alpha; a novel neuroprotective mechanism. Br J Pharmacol 152:734–743
Sun Y, Ren M, Gao GQ, Gong B, Xin W, Guo H, Zhang XJ, Gao L, Zhao JJ (2008) Chronic palmitate exposure inhibits AMPKalpha and decreases glucose-stimulated insulin secretion from beta-cells: modulation by fenofibrate. Acta Pharmacol Sin 29:443–450
Sundvold H, Lien S (2001) Identification of a novel peroxisome proliferator-activated receptor (PPAR) gamma promoter in man and transactivation by the nuclear receptor RORalpha1. Biochem Biophys Res Commun 287:383–390
Sung CK, She H, Xiong S, Tsukamoto H (2004) Tumor necrosis factor-alpha inhibits peroxisome proliferator-activated receptor gamma activity at a posttranslational level in hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol 286:G722–G729
Swarbrick MM, Chapman CM, McQuillan BM, Hung J, Thompson PL, Beilby JP (2001) A Pro12Ala polymorphism in the human peroxisome proliferator-activated receptor-gamma 2 is associated with combined hyperlipidaemia in obesity. Eur J Endocrinol 144:277–282
Syversen U, Stunes AK, Gustafsson BI, Obrant KJ, Nordsletten L, Berge R, Thommesen L, Reseland JE (2009) Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)alpha agonist fenofibrate and the PPARgamma agonist pioglitazone. BMC Endocr Disord 9:10
Szanto A, Narkar V, Shen Q, Uray IP, Davies PJ, Nagy L (2004) Retinoid X receptors: X-ploring their (patho) physiological functions. Cell Death Differ 11:S126–S143
Szatmari I, Vámosi G, Brazda P, Balint BL, Benko S, Széles L, Jeney V, Ozvegy-Laczka C, Szántó A, Barta E, Balla J, Sarkadi B, Nagy L (2006) Peroxisome proliferator-activated receptor gamma-regulated ABCG2 expression confers cytoprotection to human dendritic cells. J Biol Chem 281:23812–23823
Tahara T, Arisawa T, Shibata T, Nakamura M, Wang F, Maruyama N, Kamiya Y, Nakamura M, Fujita H, Nagasaka M, Iwata M, Takahama K, Watanabe M, Hirata I, Nakano H (2007) Influence of peroxisome proliferator-activated receptor (PPAR)gamma Plo12Ala polymorphism as a shared risk marker for both gastric cancer and impaired fasting glucose (IFG) in Japanese. Dig Dis Sci 53:614–621
Tai ES, Corella D, Deurenberg-Yap M, Adiconis X, Chew SK, Tan CE, Ordovas JM (2004) Differential effects of the C1431T and Pro12Ala PPARgamma gene variants on plasma lipids and diabetes risk in an Asian population. J Lipid Res 45:674–6785
Takahashi N, Okumura T, Motomura W, Fujimoto Y, Kawabata I, Kohgo Y (1999) Activation of PPARgamma inhibits cell growth and induces apoptosis in human gastric cancer cells. FEBS Lett 455:135–139
Takahashi Y, Hasegawa-Moriyama M, Sakurai T, Inada E (2011) The macrophage-mediated effects of the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone attenuate tactile allodynia in the early phase of neuropathic pain development. Anesth Analg 113:398–404
Takaki K, Mitsuyama K, Tsuruta O, Toyonaga A, Sata M (2006) Attenuation of experimental colonic injury by thiazolidinedione agents. Inflamm Res 55:10–15
Takata Y, Liu J, Yin F, Collins AR, Lyon CJ, Lee CH, Atkins AR, Downes M, Barish GD, Evans RM, Hsueh WA, Tangirala RK (2008) PPARdelta-mediated antiinflammatory mechanisms inhibit angiotensin II-accelerated atherosclerosis. Proc Natl Acad Sci USA 105:4277–4282
Tamaki J, Iki M, Morita A, Ikeda Y, Sato Y, Kajita E, Kagamimori S, Kagawa Y, Yoneshima H (2010) Peroxisome proliferator-activated receptor gamma polymorphism is related to peak bone mass: the JPOS study. Osteoporos Int 21:321–329
Tan NS, Michalik L, Noy N, Yasmin R, Pacot C, Heim M, Flühmann B, Desvergne B, Wahli W (2001) Critical roles of PPAR beta/delta in keratinocyte response to inflammation. Genes Dev 15:3263–3277
Tanaka T, Yamamoto J, Iwasaki S, Asaba H, Hamura H, Ikeda Y, Watanabe M, Magoori K, Ioka RX, Tachibana K, Watanabe Y, Uchiyama Y, Sumi K, Iguchi H, Ito S, Doi T, Hamakubo T, Naito M, Auwerx J, Yanagisawa M, Kodama T, Sakai J (2003) Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc Natl Acad Sci USA 100:15924–15929
Tarrade A, Schoonjans K, Guibourdenche J, Bidart JM, Vidaud M, Auwerx J, Rochette-Egly C, Evain-Brion D (2001) PPAR gamma/RXR alpha heterodimers are involved in human CG beta synthesis and human trophoblast differentiation. Endocrinology 142:4504–4514
Tenebaum A, Fisman E (2012) Fibrates are an essential part of modern antidyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction. Cardiovasc Diabetol 11:125
Thevis M, Möller I, Thomas A, Beuck S, Rodchenkov G, Bornatsch W, Geyer H, Schänzer W (2010) Characterization of two major urinary metabolites of the PPARdelta-agonist GW1516 and implementation of the drug in routine doping controls. Anal Bioanal Chem 396:2479–2491
Thoms S, Gärtner J (2012) First PEX11β patient extends spectrum of peroxisomal biogenesis disorder phenotypes. J Med Genet 49:314–316
Throp JM, Waring WS (1962) Modification of metabolism and distribution of lipids by ethyl chlorophenoxyisobutyrate. Nature 194:948–949
Thuillier P, Anchiraico GJ, Nickel KP, Maldve RE, Gimenez-Conti I, Muga SJ, Liu KL, Fischer SM, Belury MA (2000) Activators of peroxisome proliferator-activated receptor-alpha partially inhibit mouse skin tumor promotion. Mol Carcinog 29:134–142
Thulin P, Glinghammar B, Skogsberg J, Lundell K, Ehrenborg E (2008) PPARdelta increases expression of the human apolipoprotein A-II gene in human liver cells. Int J Mol Med 21:819–824
Tikoo K, Kumar P, Gupta J (2009) Rosiglitazone synergizes anticancer activity of cisplatin and reduces its nephrotoxicity in 7, 12-dimethyl benz{a}anthracene (DMBA) induced breast cancer rats. BMC Cancer 9:107
Till A, Lakhani R, Burnett SF, Subramani S (2012) Pexophagy: the selective degradation of peroxisomes. Int J Cell Biol 2012:512721
Timsit YE, Negishi M (2007) CAR and PXR: the xenobiotic-sensing receptors. Steroids 72:231–246
Toblli JE, Ferrini MG, Cao G, Vernet D, Angerosa M, Gonzalez-Cadavid NF (2009) Antifibrotic effects of pioglitazone on the kidney in a rat model of type 2 diabetes mellitus. Nephrol Dial Transplant 24:2384–2391
Tomaru T, Satoh T, Yoshino S, Ishizuka T, Hashimoto K, Monden T, Yamada M, Mori M (2006) Isolation and characterization of a transcriptional cofactor and its novel isoform that bind the deoxyribonucleic acid-binding domain of peroxisome proliferator-activated receptor-gamma. Endocrinology 147:377–388
Tontonoz P, Hu E, Graves RA, Budavari AI, Spiegelman BM (1994) mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev 8:1224–1234
Tordjman K, Standley KN, Bernal-Mizrachi C, Leone TC, Coleman T, Kelly DP, Semenkovich CF (2002) PPARalpha suppresses insulin secretion and induces UCP2 in insulinoma cells. J Lipid Res 43:936–943
Toyoda M, Takagi H, Horiguchi N, Kakizaki S, Sato K, Takayama H, Mori M (2002) A ligand for peroxisome proliferator activated receptor gamma inhibits cell growth and induces apoptosis in human liver cancer cells. Gut 50:563–567
Toyota M, Miyazaki Y, Kitamura S, Nagasawa Y, Kiyohara T, Shinomura Y, Matsuzawa Y (2002) Peroxisome proliferator-activated receptor gamma reduces the growth rate of pancreatic cancer cells through the reduction of cyclin D1. Life Sci 70:1565–1575
Trivedi NR, Cong Z, Nelson AM, Albert AJ, Rosamilia LL, Sivarajah S, Gilliland KL, Liu W, Mauger DT, Gabbay RA, Thiboutot DM (2006) Peroxisome proliferator-activated receptors increase human sebum production. J Invest Dermatol 126:2002–2009
Tsubouchi Y, Sano H, Kawahito Y, Mukai S, Yamada R, Kohno M, Inoue K, Hla T, Kondo M (2000) Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-gamma agonists through induction of apoptosis. Biochem Biophys Res Commun 270:400–405
Tsujie M, Nakamori S, Okami J, Hayashi N, Hiraoka N, Nagano H, Dono K, Umeshita K, Sakon M, Monden M (2003) Thiazolidinediones inhibit growth of gastrointestinal, biliary, and pancreatic adenocarcinoma cells through activation of the peroxisome proliferator-activated receptor gamma/retinoid X receptor alpha pathway. Exp Cell Res 289:143–151
Tsukahara T, Tsukahara R, Fujiwara Y, Yue J, Cheng Y, Guo H, Bolen A, Zhang C, Balazs L, Re F, Du G, Frohman MA, Baker DL, Parrill AL, Uchiyama A, Kobayashi T, Murakami-Murofushi K, Tigyi G (2010) Phospholipase D2-dependent inhibition of the nuclear hormone receptor PPARgamma by cyclic phosphatidic acid. Mol Cell 39:421–432
Tudor C, Feige JN, Pingali H, Lohray VB, Wahli W, Desvergne B, Engelborghs Y, Gelman L (2007) Association with coregulators is the major determinant governing peroxisome proliferator-activated receptor mobility in living cells. J Biol Chem 282:4417–4426
Turmelle YP, Shikapwashya O, Tu S, Hruz PW, Yan Q, Rudnick DA (2006) Rosiglitazone inhibits mouse liver regeneration. FASEB J 20:2609–2611
Uchida A, Slipchenko MN, Cheng JX, Buhman KK (2011) Fenofibrate, a peroxisome proliferator-activated receptor α agonist, alters triglyceride metabolism in enterocytes of mice. Biochim Biophys Acta 1811:170–176
Uchimura K, Nakamuta M, Enjoji M, Irie T, Sugimoto R, Muta T, Iwamoto H, Hawata H (2001) Activation of retinoic X receptor and peroxisome proliferator-activated receptor-γ inhibits nitric oxide and tumor necrosis factor-α production in rat kupffer cells. Hepatology 33:91–99
Ueyama J, Kitaichi K, Nadai M, Iwase M, Tomyo N, Kanazawa H, Suzuki R, Takagi K, Takagi K, Hasegawa T (2004) Effect of pioglitazone on endotoxin-induced decreases in hepatic drug-metabolizing enzyme activity and expression of CYP3A2 and CYP2C11. Eur J Pharmacol 498:257–265
Uruno A, Matsuda K, Noguchi N, Yoshikawa T, Kudo M, Satoh F, Rainey WE, Hui XG, Akahira J, Nakamura Y, Sasano H, Okamoto H, Ito S, Sugawara A (2011) Peroxisome proliferator-activated receptor-{gamma} suppresses CYP11B2 expression and aldosterone production. J Mol Endocrinol 46:37–49
Valve R, Sivenius K, Miettinen R, Pihlajamäki J, Rissanen A, Deeb SS, Auwerx J, Uusitupa M, Laakso M (1999) Two polymorphisms in the peroxisome proliferator-activated receptor-gamma gene are associated with severe overweight among obese women. J Clin Endocrinol Metab 84:3708–3712
Van der Veen JN, Kruit JK, Havinga R, Baller JF, Chimini G, Lestavel S, Staels B, Groot PH, Groen AK, Kuipers F (2005) Reduced cholesterol absorption upon PPARdelta activation coincides with decreased intestinal expression of NPC1L1. J Lipid Res 46:526–534
Varga T, Czimmerer Z, Nagy L (2011) PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation. Biochim Biophys Acta 1812:1007–1022
Venegas-Pont M, Sartori-Valinotti JC, Maric C, Racusen LC, Glover PH, McLemore GR Jr, Jones AV, Reckelhoff JF, Ryan MJ (2009) Rosiglitazone decreases blood pressure and renal injury in a female mouse model of systemic lupus erythematosus. Am J Physiol Regul Integr Comp Physiol 296:R1282–R1289
Vidal-Puig A, Considine R, Jimenez-Linan M, Werman A, Porries W, Caro J, Flier J (1997) Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss and regulation by insulin and glucocorticoids. J Clin Invest 99:2416–2422
Villard P, Barlesi F, Armand M, Dao T, Pascussi J, Fouchier F, Champion S, Dufour C, Giniès C, Khalil A, Amiot MJ, Barra Y, Seree E (2011) CYP1A1 induction in the colon by serum: involvement of the PPARα pathway and evidence for a new specific human PPREα site. PLoS One 6:e14629
Villegas I, Martín AR, Toma W, de la Lastra CA (2004) Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, protects against gastric ischemia-reperfusion damage in rats: role of oxygen free radicals generation. Eur J Pharmacol 505:195–203
Wagner ER, He BC, Chen L, Zuo GW, Zhang W, Shi Q, Luo Q, Luo X, Liu B, Luo J, Rastegar F, He CJ, Hu Y, Boody B, Luu HH, He TC, Deng ZL, Haydon RC (2010) Therapeutic implications of PPARgamma in human osteosarcoma. PPAR Res 2010:956427
Waku T, Shiraki T, Oyama T, Maebara K, Nakamori R, Morikawa K (2010) The nuclear receptor PPARγ individually responds to serotonin- and fatty acid-metabolites. EMBO J 29:3395–3407
Wan Y, Chong LW, Evans RM (2007) PPAR-gamma regulates osteoclastogenesis in mice. Nat Med 13:1496–1503
Wan J, Jiang L, Lü Q, Ke L, Li X, Tong N (2009) Activation of PPARdelta up-regulates fatty acid oxidation and energy uncoupling genes of mitochondria and reduces palmitate-induced apoptosis in pancreatic beta-cells. Biochem Biophys Res Commun 391:1567–1572
Wanders RJ, Waterham HR (2005) Peroxisomal disorders I: biochemistry and genetics of peroxisome biogenesis disorders. Clin Genet 67:107–133
Wanders RJ, Ferdinandusse S, Brites P, Kemp S (2010) Peroxisomes, lipid metabolism and lipotoxicity. Biochim Biophys Acta 1801:272–280
Wanders RJ, Komen J, Kemp S (2011) Fatty acid omega-oxidation as a rescue pathway for fatty acid oxidation disorders in humans. FEBS J 278:182–194
Wang YX, Lee CH, Tiep S, Yu RT, Ham J, Kang H, Evans RM (2003) Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity. Cell 113:159–170
Wang YX, Zhang CL, Yu RT, Cho HK, Nelson MC, Bayuga-Ocampo CR, Ham J, Kang H, Evans RM (2004) Regulation of muscle fiber type and running endurance by PPARdelta. PLoS Biol 2:e294
Ward JE, Tan X (2007) Peroxisome proliferator activated receptor ligands as regulators of airway inflammation and remodelling in chronic lung disease. PPAR Res 2007:14983
Watkins PB, Whitcomb RW (1998) Hepatic dysfunction associated with troglitazone. N Engl J Med 338:916–917
Weber SM, Scarim AL, Corbett JA (2003) PPARgamma is not required for the inhibitory actions of PGJ2 on cytokine signaling in pancreatic beta-cells. Am J Physiol Endocrinol Metab 286:E329–E336
Weller S, Gould SJ, Valle D (2003) Peroxisome biogenesis disorders. Annu Rev Genomics Hum Genet 4:165–211
Welters HJ, McBain SC, Tadayyon M, Scarpello JH, Smith SA, Morgan NG (2004) Expression and functional activity of PPARgamma in pancreatic beta cells. Br J Pharmacol 142:1162–1170
Wierzbicki M, Chabowski A, Zendzian-Piotrowska M, Gorski J (2009a) Differential effects of in vivo PPAR alpha and gamma activation on fatty acid transport proteins expression and lipid content in rat liver. J Physiol Pharmacol 60:99–106
Wierzbicki M, Chabowski A, Zendzian-Piotrowska M, Harasim E, Górski J (2009b) Chronic, in vivo, PPARalpha activation prevents lipid overload in rat liver induced by high fat feeding. Adv Med Sci 54:59–65
Wilson TW, Alonso-Galicia M, Roman RJ (1998) Effects of lipid-lowering agents in the Dahl salt-sensitive rat. Hypertension 31:225–231
Winkelmayer W, Setoguchi S, Levin R, Solomon D (2008) Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy. Arch Intern Med 168:2368–2375
Winzell MS, Wulff EM, Olsen GS, Sauerberg P, Gotfredsen CF, Ahrén B (2010) Improved insulin sensitivity and islet function after PPARdelta activation in diabetic db/db mice. Eur J Pharmacol 626:297–305
Woerly G, Honda K, Loyens M, Papin JP, Auwerx J, Staels B, Capron M, Dombrowicz D (2003) Peroxisome proliferator-activated receptors alpha and gamma down-regulate allergic inflammation and eosinophil activation. J Exp Med 198:411–421
Wölkart G, Schrammel A, Dörffel K, Haemmerle G, Zechner R, Mayer B (2011) Cardiac dysfunction in adipose triglyceride lipase deficiency: treatment with a PPARα agonist. Br J Pharmacol 165:380–389
Woods C, Kosyk O, Bradford B, Ross P, Burns A, Cunningham M, Qu P, Ibrahim J, Rusyn I (2007) Time-course investigation of PPARα- and Kupffer cell-dependent effects of WY 14643 in mouse liver using microarray gene expression. Toxicol Appl Pharmacol 225:267–277
www.clinicaltrials.gov
Xu HE, Lambert MH, Montana VG, Plunket KD, Moore LB, Collins JL, Oplinger JA, Kliewer SA, Gampe RT Jr, McKee DD, Moore JT, Willson TM (2001) Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors. Proc Natl Acad Sci USA 98:13919–13924
Xu L, Han C, Lim K, Wu T (2006) Cross-talk between peroxisome proliferator-activated receptor delta and cytosolic phospholipase A(2)alpha/cyclooxygenase-2/prostaglandin E(2) signaling pathways in human hepatocellular carcinoma cells. Cancer Res 66:11859–11868
Xu SQ, Li YH, Hu SH, Chen K, Dong LY (2008) Effects of Wy14643 on hepatic ischemia reperfusion injury in rats. World J Gastroenterol 14:6936–6942
Yamamoto K, Ohki R, Lee RT, Ikeda U, Shimada K (2001) Peroxisome proliferator-activated receptor gamma activators inhibit cardiac hypertrophy in cardiac myocytes. Circulation 104:1670–1675
Yamamoto Y, Ono T, Dhar DK, Yamanoi A, Tachibana M, Tanaka T, Nagasue N (2008) Role of peroxisome proliferator-activated receptor-gamma (PPARgamma) during liver regeneration in rats. J Gastroenterol Hepatol 23:930–937
Yamamoto-Furusho JK, Peñaloza-Coronel A, Sánchez-Muñoz F, Barreto-Zuñiga R, Dominguez-Lopez A (2011) Peroxisome proliferator-activated receptor-gamma (PPAR-γ) expression is downregulated in patients with active ulcerative colitis. Inflamm Bowel Dis 17:680–681
Yang L, Chan CC, Kwon OS, Liu S, McGhee J, Stimpson SA, Chen LZ, Harrington WW, Symonds WT, Rockey DC (2006) Regulation of peroxisome proliferator-activated receptor-gamma in liver fibrosis. Am J Physiol Gastrointest Liver Physiol 291:G902–G911
Yang Q, Nagano T, Shah Y, Cheung C, Ito S, Gonzalez FJ (2008a) The PPAR alpha-humanized mouse: a model to investigate species differences in liver toxicity mediated by PPAR alpha. Toxicol Sci 101:132–139
Yang J, Chen L, Zhang X, Zhou Y, Zhang D, Huo M, Guan Y (2008b) PPARs and female reproduction: evidence from genetically manipulated mice. PPAR Res 2008:723243
Yang X, Kume S, Tanaka Y, Isshiki K, Araki S, Chin-Kanasaki M, Sugimoto T, Koya D, Haneda M, Sugaya T, Li D, Han P, Nishio Y, Kashiwagi A, Maegawa H, Uzu T (2011) GW501516, a PPARδ agonist, ameliorates tubulointerstitial inflammation in proteinuric kidney disease via inhibition of TAK1-NFκB pathway in mice. PLoS One 6:e25271
Yen CJ, Beamer BA, Negri C, Silver K, Brown KA, Yarnall DP, Burns DK, Roth J, Shuldiner AR (1997) Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR gamma) gene in diabetic Caucasians: identification of a Pro12Ala PPAR gamma 2 missense mutation. Biochem Biophys Res Commun 241:270–274
Yi JH, Park SW, Brooks N, Lang BT, Vemuganti R (2008) PPARgamma agonist rosiglitazone is neuroprotective after traumatic brain injury via anti-inflammatory and anti-oxidative mechanisms. Brain Res 1244:164–172
Yokota S (2003) Degradation of normal and proliferated peroxisomes in rat hepatocytes: regulation of peroxisomes quantity in cells. Microsc Res Tech 61:151–160
Yokota S, Fahimi HD (2009) Degradation of excess peroxisomes in mammalian liver cells by autophagy and other mechanisms. Histochem Cell Biol 131:455–458
York M, Abdelrahim M, Chintharlapalli S, Lucero SD, Safe S (2007) 1,1-bis(3'-indolyl)-1-(p-substitutedphenyl)methanes induce apoptosis and inhibit renal cell carcinoma growth. Clin Cancer Res 13:6743–6752
Yoshizaki T, Motomura W, Tanno S, Kumei S, Yoshizaki Y, Tanno S, Okumura T (2010) Thiazolidinediones enhance vascular endothelial growth factor expression and induce cell growth inhibition in non-small-cell lung cancer cells. J Exp Clin Cancer Res 29:22
Yoshizato K, Tateno C (2009) Human hepatocyte-baring mouse: an animal model to predict drug metabolism and effectiveness in human. PPAR Res 2009:476217
Younk LM, Uhl L, Davis SN (2011) Pharmacokinetics, efficacy and safety of aleglitazar for the treatment of type 2 diabetes with high cardiovascular risk. Expert Opin Drug Metab Toxicol 7:7537–7763
Youssef J, Badr M (1997) Activated Kuppfer cells attenuate the liver response to the peroxisome proliferator perfluoroocatanoic acid. Mol Cell Biochem 169:143–147
Youssef J, Badr M (1999) Biology of senescent liver peroxisomes: role in hepatocellular aging and disease. Environ Health Perspect 107:791–797
Youssef J, Badr M (2001) Peroxisomal alterations in aging and disease. In interorganellar signaling in age-related disease. In: Mattson M (ed) Advances in cell aging and gerontology, vol 7. Elsevier, Amsterdam, pp 1–28
Youssef J, Badr M (2011) Peroxisomal proliferator-activated receptors and cancer: challenges and opportunities. Br J Pharmacol 164:68–82
Yu J, Leung WK, Chen J, Ebert MP, Malfertheiner P, Sung JJ (2005) Expression of peroxisome proliferator-activated receptor delta in human gastric cancer and its response to specific COX-2 inhibitor. Cancer Lett 223:11–17
Yu J, Zhang S, Chu ES, Go MY, Lau RH, Zhao J, Wu CW, Tong L, Zhao J, Poon TC, Sung JJ (2010) Peroxisome proliferator-activated receptors gamma reverses hepatic nutritional fibrosis in mice and suppresses activation of hepatic stellate cells in vitro. Int J Biochem Cell Biol 42:948–957
Yue TL, Bao W, Gu JL, Cui J, Tao L, Ma XL, Ohlstein EH, Jucker BM (2005) Rosiglitazone treatment in Zucker diabetic fatty rats is associated with ameliorated cardiac insulin resistance and protection from ischemia/reperfusion-induced myocardial injury. Diabetes 54:554–562
Zamek-Gliszczynski M, Nezasa K, Tian X, Bridges A, Lee K, Belinsky M, Kruh G, Brouwer K (2006) Evaluation of the role of multidrug resistance-associated protein (Mrp) 3 and Mrp4 in hepatic basolateral excretion of sulfate and glucuronide metabolites of acetaminophen, 4-methylumbelliferone, and harmol in Abcc3−/− and Abcc4−/− mice. J Pharmacol Exp Ther 319:1485–1491
Zamir I, Zhang J, Lazar MA (1997) Stoichiometric and steric principles governing repression by nuclear hormone receptors. Genes Dev 11:835–846
Zhang H, Zhang A, Kohan DE, Nelson RD, Gonzalez FJ, Yang T (2005) Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention. Proc Natl Acad Sci USA 102:9406–9411
Zhang F, Lavan BE, Gregoire FM (2007) Selective modulators of PPAR-gamma activity: molecular aspects related to obesity and side-effects. PPAR Res 2007:32696
Zhao X, Li L (2008) PPAR-alpha agonist fenofibrate induces renal CYP enzymes and reduces blood pressure and glomerular hypertrophy in Zucker diabetic fatty rats. Am J Nephrol 28:598–606
Zhao X, Quigley J, Yuan J, Wang M, Zhou Y, Imig J (2006) PPAR-alpha activator fenofibrate increases renal CYP-derived eicosanoid synthesis and improves endothelial dilator function in obese Zucker rats. Am J Physiol Heart Circ Physiol 290:H2187–H2195
Zhou YT, Shimabukuro M, Wang MY, Lee Y, Higa M, Milburn JL, Newgard CB, Unger RH (1998) Role of peroxisome proliferator-activated receptor alpha in disease of pancreatic beta cells. Proc Natl Acad Sci USA 95:8898–9803
Zhou Y, Luo P, Chang HH, Huang H, Yang T, Dong Z, Wang CY, Wang MH (2008a) Colfibrate attenuates blood pressure and sodium retention in DOCA-salt hypertension. Kidney Int 74:1040–1048
Zhou YM, Wen YH, Kang XY, Qian HH, Yang JM, Yin ZF (2008b) Troglitazone, a peroxisome proliferator-activated receptor gamma ligand, induces growth inhibition and apoptosis of HepG2 human liver cancer cells. World J Gastroenterol 14:2168–2173
Zhou Y, Kong X, Zhao P, Yang H, Chen L, Miao J, Zhang X, Yang J, Ding J, Guan Y (2011) Peroxisome proliferator-activated receptor-α is renoprotective in doxorubicin-induced glomerular injury. Kidney Int 79:1302–1311
Zhu Y, Qi C, Korenberg JR, Chen XN, Noya D, Rao MS, Reddy JK (1995) Structural organization of mouse peroxisome proliferator-activated receptor gamma (mPPAR gamma) gene: alternative promoter use and different splicing yield two mPPAR gamma isoforms. Proc Natl Acad Sci USA 92:7921–7925
Zhu B, Bai R, Kennett MJ, Kang BH, Gonzalez FJ, Peters JM (2010) Chemoprevention of chemically induced skin tumorigenesis by ligand activation of peroxisome proliferator-activated receptor-beta/delta and inhibition of cyclooxygenase 2. Mol Cancer Ther 9:3267–3277
Zhu C, Huang S, Yuan Y, Ding G, Chen R, Liu B, Yang T, Zhang A (2011) Mitochondrial dysfunction mediates aldosterone-induced podocyte damage: a therapeutic target of PPARγ. Am J Pathol 178:2020–2031
Zieleniak A, Wójcik M, Woźniak LA (2008) Structure and physiological functions of the human peroxisome proliferator-activated receptor gamma. Arch Immunol Ther Exp (Warsz) 56:331–345
Ziouzenkova O, Perrey S, Asatryan L, Hwang J, MacNaul KL, Moller DE, Rader DJ, Sevanian A, Zechner R, Hoefler G, Plutzky J (2003) Lipolysis of triglyceride-rich lipoproteins generates PPAR ligands: evidence for an antiinflammatory role for lipoprotein lipase. Proc Natl Acad Sci USA 100:2730–2735
Ziyadeh N, McAfee A, Koro C, Landon J, Arnold CK (2009) The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database. Clin Ther 31:2665–2677
Zoete V, Grosdidier A, Michielin O (2007) Peroxisome proliferator-activated receptor structures: ligand specificity, molecular switch and interactions with regulators. Biochim Biophys Acta 1771:915–925
Zutphen T, Veenhuis M, van der Klei I (2008) Pex14 is the sole component of the peroxisomal translocon that is required for pexophagy. Autophagy 4:63–66
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this chapter
Cite this chapter
Youssef, J.A., Badr, M.Z. (2013). Tissue Distribution and Versatile Functions of PPARs. In: Peroxisome Proliferator-Activated Receptors. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-420-3_5
Download citation
DOI: https://doi.org/10.1007/978-1-62703-420-3_5
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-62703-419-7
Online ISBN: 978-1-62703-420-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)